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ABSTRACT
Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute
lymphoblastic leukemia in adults (>15 years) is presented and critically evaluated in this systematic evidence-
based review. Specific criteria were used for searching the published medical literature and for grading the
quality and strength of the evidence, and the strength of the treatment recommendations. Treatment recom-
mendations based on the evidence are presented and were reached unanimously by a panel of acute lympho-
blastic leukemia experts. The priority areas of needed future research for adult acute lymphoblastic leukemia
are: definition of patients at high risk in first complete remission, beyond Philadelphia chromosome positive;
outcomes of SCT in older (>50 years) adults; determination if reduced intensity versus myeloablative condi-
tioning regimens yield an equivalent graft-versus-leukemia effect with reduced toxicity; monitoring of minimal
residual disease to achieve disease control before SCT; and the use of cord blood and other alternative sources
of stem cells for use in adult SCT recipients.
© 2006 American Society for Blood and Marrow Transplantation
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(NTRODUCTION
The American Society for Blood and Marrow
ransplantation (ASBMT) in 1999 began an initiative
o sponsor evidence-based reviews of the scientiﬁc and
edical literature for the use of hematopoietic stem
ell transplantation (SCT) in the therapy of selected
iseases. The steering committee that was convened
o oversee the projects invited an independent panel of
isease-speciﬁc experts to conduct each review. Three
ll terms abbreviated in this article are deﬁned in a Glossary of Terms,
oppendix A, at the end of the article.
B &MTeviews have been published in Biology of Blood and
arrow Transplantation: diffuse large cell B-cell non-
odgkin’s lymphoma in 2001 [1]; multiple myeloma
n 2003 [2]; and pediatric acute lymphoblastic leuke-
ia (ALL) in 2005 [3]. The following is the fourth
eview to result from this initiative. Its goals are to: (1)
ssemble and critically evaluate all of the evidence
egarding the role of stem cell transplantation (SCT)
n the therapy of adult ALL; (2) make treatment rec-
mmendations based on the available evidence; and
3) identify needed areas of research.
The published literature was graded on the quality
f design and the strength of the evidence (Table 1) in
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2systematic manner. Treatment recommendations
ere subsequently graded based on the quality and
trength of the evidence (Table 2). The treatment
ecommendations of the expert panel are detailed in
able 3.
ITERATURE SEARCH METHODOLOGY
PubMed and MEDLINE, the Web sites devel-
ped by the National Center of Biotechnology Infor-
ation at the National Library of Medicine of the
ational Institutes of Health, were searched using the
earch terms “acute lymphoblastic leukemia” and
transplant” limited to human trials and English lan-
uage. The MEDLINE subject heading terms for any
rticle about ALL included acute lymphoblastic leu-
emia, acute lymphoid leukemia, and acute lympho-
ytic leukemia, regardless of which term was used in
he published article. Therefore, the search by “acute
ymphoblastic leukemia” generated all articles on ALL
ven if the article did not use this term to deﬁne ALL.
he original search included publications from Janu-
ry 1, 1980, to August 18, 2002, was updated on
ebruary 18, 2003, and underwent a ﬁnal update on
anuary 3, 2005. In addition, articles were excluded if
hey were not peer-reviewed reports; were editorials,
etters to the editor, case reports (10 patients), phase
(dose escalation or dose ﬁnding) studies, reviews,
onsensus conference reports, practice guidelines, or
able 1. Grading the Quality of Design and Strength of Evidence
Levels of
Evidence
1 High-quality meta-analyses, systematic reviews of
RCTs, or RCTs with a very low risk of bias
1 Well-conducted meta-analyses, systematic reviews
of RCTs, or RCTs with a low risk of bias
1 Meta-analyses, systematic reviews of RCTs, or
RCTs with a high risk of bias
2 High-quality systematic reviews of case control or
cohort studies
High-quality case control or cohort studies with a
very low risk of confounding, bias, or chance,
and a high probability that the relationship is
causal
2 Well-conducted case control or cohort studies
with a low risk of confounding, bias, or chance,
and a moderate probability that the relationship
is causal
2 Case control or cohort studies with a high risk of
confounding, bias, or chance, and a significant
risk that the relationship is not causal
3 Nonanalytic studies (e.g., case reports, case series)
4 Expert opinion
CTs indicates randomized controlled trials.
eprinted with permission from: Harbour R, Miller J. A new system
for grading recommendations in evidence-based guidelines. Br
Med J. 2001;323:334-336.aboratory studies with no clinical correlates; or didot focus on an aspect of therapy with SCT for the
reatment of ALL. The review of SCT for ALL is
ublished as two articles: one including studies of
ediatric ALL, and the other including studies of adult
LL. Articles are excluded from the adult ALL review
f more than 50% of the study population was younger
han 16 years; these articles were included in the
ediatric ALL review [3]. Abstracts and presentations
t national or international meetings were also not
ncluded as evidence in this review because the lack of
ormal peer review, the limited availability of details
n study design and results, and the usual presentation
s preliminary, not ﬁnal analyses of clinical trial data.
UALITATIVE AND QUANTITATIVE GRADING OF
HE EVIDENCE
The hierarchy of evidence, including a grading
cheme for the quality and strength of the evidence,
nd strength of each treatment recommendation, has
een established and published as an editorial policy
tatement in Biology of Blood and Marrow Transplanta-
ion [4]. Tables 1 and 2 are reprinted from the policy
tatement and deﬁne criteria used to grade the studies
ncluded in the review and grade the treatment rec-
mmendations. Study design, including sample size,
atient selection criteria, duration of follow-up, and
reatment plan, also were considered in evaluating the
tudies. All data in the text and tables were abstracted
able 2. Grading the Strength of the Treatment Recommendation
Grades of
Recommendation
A At least one meta-analysis, systematic
review, or RCT rated as 1, and
directly applicable to the target
population; or a systematic review of
RCTs or a body of evidence consisting
principally of studies rated as 1,
directly applicable to the target
population, and demonstrating overall
consistency of results
B A body of evidence including studies rated
as 2, directly applicable to the
target population, and demonstrating
overall consistency of results; or
extrapolated evidence from studies
rated as 1 or 1
C A body of evidence including studies rated
as 2, directly applicable to the target
population and demonstrating overall
consistency of results; or extrapolated
evidence from studies rated as 2
D Evidence level 3 or 4; or extrapolated
evidence from studies rated as 2
CT indicates randomized controlled trial.
eprinted with permission from: Harbour R, Miller J. A new system
for grading recommendations in evidence-based guidelines. Br
Med J. 2001;323:334-336.
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Cytotoxic Therapy with SCT for Adult ALL
Brom the original articles ﬁrst by one author (T. H.),
hen double-checked for accuracy and clarity by an-
ther author (P. L. M.) and at least two additional
eviewers (see acknowledgements). In some articles
here were discrepancies within the data reported, i.e.,
he median follow-up reported in the abstract was not
he same as in the results section, or data presented in
table did not agree with those in the text. In these
ases, the data most consistent with the text of the
rticle were presented in this review. The ﬁrst author
T. H.) takes responsibility if errors remain. Clini-
al studies were summarized with enough detail to
able 3. Summary of Treatment Recommendations Made by the Exper
Indication for
SCT
Treatment
Recommendation*
Highest
Level of
Evidence†
CT vs. chemotherapy
in first complete
remission
B 1
CT vs. chemotherapy
in second complete
remission
D 3
utologous purged SCT D 2
utologous, unpurged
SCT
D 2
elated allogeneic SCT C 2
nrelated allogeneic
SCT
C 2
elated vs. unrelated
allogeneic SCT
D 2
omparison of
conditioning regimens
N/A N/A
utologous vs.
allogeneic SCT
B 1
FS indicates leukemia-free survival.
Deﬁnitions: See Table 2.
Deﬁnitions: See Table 1.
The references listed represent the highest level of evidence used to
described in the review.ive a concise summary of study design, sample size, i
B&MTligibility criteria, treatment schedule, duration of
ollow-up, and outcomes measured. Subjective
tatements regarding issues such as short versus
dequate versus long follow-up, small versus large
ample size, improper or inappropriate study design
ere not used so that the reader is not biased by the
uthors’ opinions.
REATMENT RECOMMENDATIONS
The strength of this review is the detail conveyed
for Adult Acute Lymphoblastic Leukemia
ence
.‡ Comments
7 In first complete remission, SCT yields outcomes
similar to chemotherapy and is not recommended
as first choice therapy in standard-risk patients. For
high-risk patients, there are no direct comparisons,
but some data suggest an advantage for SCT.
A In second complete remission, SCT is recommended
over chemotherapy as a sizable fraction of patients
achieve extended leukemia-free survival compared
with chemotherapy alone; however, there are no
direct comparative data.
27 Leukemia-free survival is in the same range seen with
chemotherapy.
20 Leukemia-free survival is in the same range seen with
chemotherapy.
0 Effective at producing extended leukemia-free survival in
some patients. High-risk Ph ALL patients have very
poor LFS (<10%) with chemotherapy; although there
are no direct comparisons, there appears to be a
survival advantage for related allogeneic SCT in Ph
ALL patients in first or subsequent remissions.
3 Produces extended leukemia-free survival in some
patients. There is a possible benefit of unrelated
allogeneic SCT over chemotherapy in Ph ALL
patients, although there are no direct comparisons.
Higher TRM may compromise the potential
antitumor advantage of unrelated allogeneic SCT.
6 Equivalent outcomes between related and unrelated
allogeneic SCT in one study.
A There are not enough data to make a
recommendation of the superiority of one
conditioning regimen. There appears to be a benefit
to TBI-containing regimens compared with
non-TBI-containing regimens. There are not enough
data evaluating nonmyeloablative conditioning
regimens to determine the effect on TRM and
leukemia-free survival.
,67 Preponderance of evidence favoring allogeneic over
autologous SCT. There are insufficient data to
determine if this effect is more apparent in risk
subgroups, including Ph ALL.
the treatment recommendation and are not inclusive of all evidencet Panel
Refer
No
5-
N/
24-
18-
3
5
5
N/
8,66
maken the text and the study comparisons in the summary
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4ables at the end of each major section. Table 3 con-
ains the summary of treatment recommendations
ade by the ALL expert panel. Subsequent sections of
he review present the detailed descriptions of the
trengths and weaknesses of the evidence and are spe-
iﬁc to each treatment recommendation. Additional
ections describe other limitations of this review, ad-
itional ongoing studies, areas of needed research, and
uture initiatives.
There were not enough data published as of Jan-
ary 3, 2005, to determine the impact of imatinib
esylate in patients with Philadelphia chromosome–
ositive (Ph) ALL on the outcome of SCT or on the
bility to achieve higher complete remission (CR)
ates making more patients eligible for SCT. The use
f imatinib mesylate before SCT, as part of the con-
itioning regimen and after SCT, has not been ade-
uately studied to determine its effect on overall sur-
ival (OS) and leukemia-free survival (LFS).
RANSPLANTATION VERSUS CHEMOTHERAPY IN
DULT ALL
Table 4 summarizes the grading criteria, study
opulations, patient characteristics, and outcomes
rom adult studies included in the transplantation ver-
us chemotherapy section. Evidence in this section is
aken from self-described studies of adult populations
ll of which included patients at least 13 years of age.
vidence is presented with the highest quality studies
rst; studies of equal quality are presented in descend-
ng order with the largest sample size ﬁrst.
irst CR
Fiere et al. [5] performed a prospective, multi-
enter study (Leucémie Aiguë Lymphoblastique de
’Adulte [LALA]-87 trial) between 1986 and 1991 in
dult (15 years) patients with ALL comparing re-
ated allogeneic bone marrow transplantation (BMT),
utologous BMT, and chemotherapy. At time of ﬁrst
R (CR1), 436 patients and their siblings were human
eukocyte antigen (HLA) typed and those aged 15 to
0 years with an available donor (n  116) were
reated with an allogeneic BMT (n  98). The results
f the related allogeneic BMT group are summarized
n Sebban et al. [6] below. Patients younger than 40
ears with no available related donor, and patients
etween 40 and 50 years old (n  262) were random-
zed to receive either an autologous BMT (n  95
andomized, actual BMT in 63 patients) or chemo-
herapy (n 96). All patients older than 50 years were
reated with chemotherapy (n  58). Adjustment for
ime to transplantation bias was not performed; how-
ver, median time from CR1 to allogeneic BMT was
3 days and median time from CR1 to autologous
MT was 116 days. wAt a median follow-up of 38 months, the autolo-
ous BMT and chemotherapy groups did not have a
igniﬁcant difference in either disease-free survival
DFS) (3-year DFS 39% versus 32%, respectively;
 .8; Figure 1) or OS (3-year OS 49% versus 42%,
espectively; P  .9). By intent-to-treat analysis, the
llogeneic BMT group had a 3-year DFS of 43% and
3-year OS of 55%. The chemotherapy group (age 
0 years) had a 3-year DFS of 24% and a 3-year OS of
8%. Factors associated with poor outcome were age,
h ALL, immunophenotype, white blood cell count
WBC) greater than 30,000/L at diagnosis, and
latelet count less than 100,000/L at diagnosis.
Thomas et al. [7] performed a prospective multi-
enter partially randomized (LALA-94) trial from
994 to 2002 in adult (15 years) patients with ALL
omparing related allogeneic SCT, autologous SCT,
nd chemotherapy. A total of 1000 patients were en-
olled and underwent induction (n  922 eligible
atients) and consolidation (n  706) chemotherapy.
atients at standard risk (n  430) received only che-
otherapy and comprised all patients with T-lineage
LL achieving CR1 after one course of chemotherapy
nd with B-lineage ALL with no central nervous sys-
em (CNS) involvement, absence of Ph, t(4;11), t(1;
9), or other 11q23 rearrangements, WBC less than
0  109/L, CD10/CD19 immunophenotype,
D20/CD19 immunophenotype and the absence
f myeloid markers, and achievement of CR1 after
ne course of chemotherapy. Patients at high risk with
on-Ph and non-CNS ALL (n 238) who achieved
R1 (n  211) and did not have a sibling donor (n 
29) were randomized to receive autologous SCT
ollowed by 2-year maintenance with methotrexate
MTX) and mercaptopurine (n  70) versus chemo-
herapy (n  59). Those with an HLA–matched sib-
ing donor received a related allogeneic SCT (n 82).
onditioning regimens for both autologous and allo-
eneic SCT were cyclophosphamide (Cy) plus total
ody irradiation (TBI) (1000 cGy in a single fraction
r 1200 cGy in 6 fractions). Graft-versus-host disease
GVHD) prophylaxis consisted of cyclosporine (CSA)
MTX; all grafts were T-cell replete. At a median
ollow-up of 5.2 years, the 3-year DFS in the autolo-
ous SCT versus chemotherapy group was 39% ver-
us 24% (P  not signiﬁcant; Figure 2).
An additional 198 patients with Ph ALL who
chieved CR1 (n 140) were biologically randomized
o receive a related allogeneic SCT if a suitable donor
as available (n  75) or an autologous SCT (n  65)
nd the results are presented by Dombret et al [8]. A
ourth group of 56 patients with CNS-positive ALL
ho achieved CR1 (n  48) were biologically ran-
omized to receive a related allogeneic SCT if a suit-
ble donor was available (n  18) or an autologous
CT (n  30). This group’s results were combined
ith the related allogeneic and autologous SCT/che-
Table 4. Comparison of Patient Characteristics and Outcomes from Articles Included in the Transplantation Versus Chemotherapy in Adult Acute Lymphoblastic Leukemia in First Complete Remission Section
Reference
Quality and
Strength of
Evidence
Patient
Populations
No. of Patients
by Treatment
Regimen
Median (range)
Age at Time of
Therapy
Treatment-
Related
Mortality
Median
Follow-Up
(mos) LFS/EFS/DFS
Significance
LFS/EFS/DFS OS
Significance
OS
Auto SCT vs. Chemotherapy
5 1 LALA-87 trial* Total 191
Auto BMT 95
Chemo 96
25 (15-50)
28 (15-48)
Overall
4%
4%
38 3-y DFS
39%
32%
Not significant 3 y
49%
42%
Not significant
7 1 LALA-94 trial Total 129
Auto PBSCT 70
Chemo 59
33 (15-55)† At 3 y
0%
7%
62† 3-y DFS
39%
24%
Not significant 3 y
44%
35%
Not stated
Related Allo SCT vs. Chemotherapy / Auto SCT
7 1 LALA-94 trial Total 259
Rel donor 100
No Rel donor 159
33 (15-55)† At 3 y
18%
7%
62† 3-y DFS
47%
34%
P  .007 3 y
51%
Not stated
Not compared
6 2 LALA-87 trial‡ Total 257
Rel Allo BMT 116
Chemo/Auto BMT 141
26 (15-40)
24 (15-40)
Overall
16%
3%
62 5 y DFS
45%
31%
Not significant 5 y
48%
35%
Not significant
9-11 2 IBMTR vs. two
German
cooperative
group trials
Total 718
Rel Allo BMT 234
Chemo 484
Not stated
(15-45)
Not stated
(15-45)
At 9 y
53%
5%
90 9-y LFS
34%
32%
Not significant Not stated Not compared
12 2 IBMTR vs.
JALSG trial
ALL-87
Total 290
Rel Allo BMT 214
Chemo 76
26 (15-51)
29 (15-55)
<30 y
32% vs. 3%
>30 y
57% vs. 13%
48
54
5-y LFS
<30 y
53% vs. 30%
>30 y
26% vs. 30%
P  .02
Not significant
Not stated Not compared
13 2 German ALL/
AUL trial
Total 76
Rel Allo BMT 38
Chemo 38§
Not stated
(15-45)
Not stated
(15-45)
Not stated Not stated 3-y DFS
34%
34%
Not significant Not stated Not compared
14 2 JALSG ALL-93
trial
Total 142
Rel donor 34
No Rel donor 108
Not stated
(15-40)
Not stated
(15-40)
Not stated 63 Not stated Not compared 6 y
46%
40%
Not significant
15 2 Single Canadian
center
Total 87
Rel donor 48
No Rel donor 39
34 (16-54)
25 (16-52)
At 1 y
19%
5%
52 3-y EFS
40%
39%
Not significant 3 y
46%
58%
Not significant
C
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Table 4. Continued
Reference
Quality and
Strength of
Evidence
Patient
Populations
No. of Patients
by Treatment
Regimen FS
Significance
LFS/EFS/DFS OS
Significance
OS
16 2 JALSG ALL-90
trial
Total 57
Rel Allo BMT 17
Chemo 40
Not compared 6 y
41%
30%
Not significant
17 2 Single Japanese
center
Total 30
Rel Allo BMT 12
Chemo 18
S Not significant Overall
80.2%
33.3%
P < .05
ALL indicates acute lymphoblastic leukemia; Allo, allogeneic; AUL, acute plantation; Chemo, standard chemotherapy comparison
group; DFS, disease-free survival; EFS, event-free survival; IBMTR, I dult Leukemia Study Group; LALA, Leucémie Aiguë
Lymphoblastique de l’Adulte (Adult Acute Lymphoblastic Leukemia); L l blood stem cell transplant; Rel, related; SCT, stem cell
transplantation.
*The updated results of this study were not peer reviewed (Hematol Oncol C ear follow-up are not different from the interim analysis
reported here.
†Includes all 922 patients enrolled in the trial.
‡The patient population reported in reference 6 overlaps with the patient p
§Reference 9 includes the same 484 patients with chemotherapy from whic udy.
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high-risk
group
described
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the
previous
paragraph
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donorversusno
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parison
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.007;Figure
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Median (range)
Age at Time of
Therapy
Treatment-
Related
Mortality
Median
Follow-Up
(mos) LFS/EFS/D
Not stated
(15-45)
Not stated
(14-45)
Not stated 62 Not stated
Not stated
Not stated
Overall
8%
0%
37 Overall DF
36.5%
23.4%
unclassiﬁed leukemia; Auto, autologous; BMT, bone marrow trans
nternational Bone Marrow Transplant Registry; JALSG, Japan A
FS, leukemia-free survival; OS, overall survival; PBSCT, periphera
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Cytotoxic Therapy with SCT for Adult ALL
Br OS (51 versus 30 months; P  .08) between the
llogeneic BMT and chemotherapy groups, respec-
ively.
In a subset of 96 patients with high-risk ALL,
here was a signiﬁcant beneﬁt for the allogeneic BMT
roup (n  41) compared with the chemotherapy
roup (n 55) with respect to DFS (median 21 versus
months; P  .01) and OS (median 30 versus 15
onths; P  .03; Figure 4). There was no difference
n DFS or OS between the allogeneic BMT and che-
otherapy groups in patients with standard-risk ALL.
atients with high-risk ALL had at least one of the
ollowing characteristics: (1) Ph ALL; (2) null leu-
emia or undifferentiated leukemia; or (3) common
eukemia with at least one adverse prognostic factor
age  35 years, WBC  30  109/L, or 4 weeks to
chieve CR1).
Zhang et al. [9-11] retrospectively compared re-
ated allogeneic BMT in adult patients with ALL from
8 hospitals worldwide reported to the International
MT Registry (IBMTR) (n  234) with patients
reated with chemotherapy from 44 hospitals in West
ermany (n 484). All patients were treated between
980 and 1987, were in CR1, and were 15 to 45 years
f age. Adjustments were made for time to transplan-
ation bias and differences in disease characteristics.
here were similar prognostic factors of treatment
ailure for both groups (immunophenotype, WBC at
iagnosis, and time to achieve CR1). At a median
ollow-up of 7.5 years, the 9-year LFS was 32% in the
hemotherapy group and 34% in the related alloge-
eic BMT group (P  .2). The probability of relapse
t 9 years was 66% in the chemotherapy group and
0% for the transplantation group (P  .0001).
Oh et al. [12] performed a retrospective case con-
igure 3. Disease-free survival (DFS) according to genetic random-
zation. For this analysis, patients from group 2 (211 patients) and
hose from group 4 (48 patients) were pooled. The group with a
ibling donor comprised 100 patients, whereas that with no sibling
onor included 159 patients. CR, complete remission. Reprinted
ith permission [7].rol study of 76 patients treated with chemotherapy R
B&MTrom trial ALL-87 of the Japan Adult Leukemia Study
roup (JALSG) and 214 patients with related HLA–
atched allogeneic BMT from the IBMTR. There is
o overlap with the patients reported in Zhang et al.
9-11] above. All patients were diagnosed with ALL
rom 1988 to 1990, were 15 to 55 years old, and
reated in CR1. Adjustments were made for time to
ransplantation bias and differences in baseline char-
cteristics. The 5-year LFS in patients age 30 years or
ounger was 30% for the chemotherapy group and
3% for the BMT group (P  .02). However, there
as no signiﬁcant difference in LFS between the che-
otherapy and BMT groups for patients older than
0 years (26% versus 30%; P  .70).
Messerer et al. [13] reported the German ALL/
UL study of 484 patients treated between 1980 and
986 with chemotherapy and 41 patients treated be-
ween 1981 and 1988 with related HLA–matched al-
ogeneic BMT in CR1 [13]. The 484 patients treated
ith chemotherapy in this study are the same 484
atients treated with chemotherapy from the Zhang et
l. [9-11] study noted above. In the study by Messerer
t al. [13], a retrospective matched case control anal-
sis was performed by selecting 38 patients from each
roup. Case and control patients were matched on sex,
ge, WBC at diagnosis, immunophenotype, and time
o reach CR1; analyses were made adjusting for time
o transplantation bias. There was no difference in the
-year DFS between the two groups (34% versus
4%).
Takeuchi et al. [14] presented the results of the
rospective multicenter JALSG-ALL-93 study con-
ucted from 1993 to 1997 in patients in CR1 who
ere younger than 40 years comparing those with
LA–matched sibling donors (related allogeneic
MT group, n  34) to those without (chemotherapy
igure 4. Overall survival of patients with high-risk leukemia ac-
ording to allocation arm. (Solid line BMT; dashed line control).
eprinted with permission [6].
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8roup, n  108). Patients in the chemotherapy group
eceived chemotherapy (n 81), unrelated BMT (n
7), autologous peripheral blood SCT (PBSCT) (n 
), or autologous BMT (n  2). The 6-year OS was
ot signiﬁcantly different between the related alloge-
eic BMT and chemotherapy groups (46% versus
0%; P  .58). OS was also not signiﬁcantly different
hen comparing actual treatment received (BMT [n
41] versus chemotherapy [n  91], excluding 10
atients with autologous BMT/PBSCT).
Gupta et al. [15] reported a single Canadian center
xperience from 1992 to 2001 offering all adult (16
ears) patients with ALL in CR1 a matched related
llogeneic BMT if a sibling donor was available (n 
8, 35 were HLA–identical, 4 were a 1-antigen mis-
atch, and 9 were unrelated donors), otherwise 2-year
aintenance and intensiﬁcation was given with che-
otherapy only (n  39, no patients received an
utologous BMT; 6 patients received an unrelated
onor BMT). Conditioning regimen was Cy and TBI
1200 cGy in 6 fractions); GVHD prophylaxis con-
isted of CSA and MTX  methylprednisolone (MP).
t a median follow-up of 52 months and using an
ntent-to-treat approach, there was no signiﬁcant dif-
erence in 3-year OS or event-free survival (EFS)
etween the donor and no donor groups. After exclud-
ng the 17 patients with Ph ALL, there was also no
igniﬁcant difference in EFS or OS between the donor
nd no donor groups.
Ueda et al. [16] described the results of the pro-
pective, multicenter JALSG-ALL-90 study con-
ucted from 1990 to 1993 in patients with ALL in
R1 younger than 45 years old comparing those who
eceived HLA–matched related BMT (n  17) to
hose who received chemotherapy (n  40). Adjust-
ents were made for time to transplantation bias. The
-year OS was not signiﬁcantly different between the
elated allogeneic BMT and chemotherapy groups
41% versus 30%; P  .226).
Tamura et al. [17] retrospectively evaluated pa-
ients with ALLwhowere younger than 45 years in CR1
ho from 1982 to 1989 received HLA–matched re-
ated allogeneic BMT (n  12) or chemotherapy in
hose without related donors (n  18). OS was signif-
cantly higher for the related BMT group compared
ith the chemotherapy group (80.2% versus 33.3%;
 .05). DFS was not signiﬁcantly different between
he two groups (36.5% versus 23.4%; P  .05).
econd CR
There are no data comparing transplantation ver-
us chemotherapy in adult patients with ALL in sec-
nd CR (CR2). There are data for adults undergoing
CT in CR2 that will be presented in later sections as
ppropriate (i.e., comparing related and unrelated do-
or BMT in CR2). pUTOLOGOUS BMT IN ADULT ALL
Table 5 summarizes the grading criteria, study
opulations, patient characteristics, and outcomes
rom adult studies included in the Autologous BMT
ection, including unpurged, purged, and purged and
npurged autologous BMT. Evidence in this section is
aken from self-described studies of adult populations,
ll of which included patients at least 13 years of age.
vidence is presented with the highest quality studies
rst; studies of equal quality are presented in descend-
ng order with the largest sample size ﬁrst.
npurged Autologous BMT
Powles et al. [18-20] evaluated 50 consecutive
dult (15 years) patients with ALL in CR1 at a single
nited Kingdom center who received between 1984
nd 1994 either an unpurged autologous BMT (n 
8) conditioned with melphalan (Mel) plus TBI or
nmanipulated autologous PBSCT (n  12) condi-
ioned with Mel alone, followed by maintenance che-
otherapy with daily 6-mercaptopurine and weekly
TX for 2 years. Maintenance chemotherapy could
e initiated in 78.9% of BMT and 91.7% of PBSCT
ecipients. No patients with autologous BMT had
LA–identical sibling donors. After December 1992,
utologous PBSCT was offered as the preferred ther-
py regardless of donor availability. In all, 47 patients
94%) received induction and early intensiﬁcation
herapy according to the United Kingdom ALL
UKALL) X regimen B protocol. Seven patients
18%) received marrow purged in vitro with Campath-
M. No patients experienced graft failure. Overall
reatment-related mortality (TRM) was 16%. At a
edian follow-up of 40 months, the 4-year OS and
FS were 56.2% and 53.2%, respectively.
Lambertenghi Deliliers et al. [21] reported the
esults of 20 patients with ALL (85% were adult but
peciﬁc age not stated) treated with an unpurged au-
ologous BMT in CR1 (n  7), CR2 (n  8), or third
R (CR3) (n  5) at a single Italian center between
984 and 1992. Conditioning regimen was cytosine
rabinoside (Ara-c), Cy, and TBI (1000 cGy in 5
ractions) for all patients. There were no cases of early
eath or death in CR. At a median follow-up of 59
onths, the 5-year EFS was 57% for patients who
nderwent transplantation in CR1 versus 31% for
atients who underwent transplantation in CR2 or
R3 (P not stated). Patients treated after one or more
NS relapses had a 5-year EFS of 53% compared
ith those treated after a hematologic relapse with a
-year EFS of 14% (P not stated).
Carey et al. [22] performed 34 consecutive un-
urged autologous BMTs from 1984 to 1988 in 15
dult (15 years) patients with ALL and 6 patients
ith high-grade non-Hodgkin’s lymphoma. These
atients had previously been treated with the same
Table 5. Comparison of Patient Characteristics and Outcomes from the Articles in the Autologous Bone Marrow Transplantation in Adult Acute Lymphoblastic Leukemia Section
Reference
Quality and
Strength of
Evidence
Patient
Populations No. of Patients
Median (range)
Age at Time of
Transplant
Treatment-
Related
Mortality
Median
Follow-Up
(mos) LFS/EFS/DFS
Significance
LFS/EFS/DFS OS
Significance
OS
Unpurged Autologous BMT
18-20 2 Single UK center* CR1 50 26 (15-58) 16% 40 4-y DFS
53.2%
Not compared 4 y
56.2%
Not compared
21 2 Single Italian center Total 20
CR1 7
CR2/3 13
18 (10-39) 0% 59 5-y EFS
57%
31%
Not compared Not stated Not compared
22-23 2 UK NE ALL III trial CR1 15 31 (15-50) 0% 30 3-y DFS
48%
Not compared Not stated Not compared
Purged Autologous BMT
24,25 2 Single German
center
CR>2 or high-risk
CR1 32
24 (13-52) 12.5% 143 12-y DFS
37.5%
Not compared 12 y
37.5%
Not compared
26 2 Single UK center CR1 27 18 (11-45) 7% 41 7-y DFS
32%
Not compared Not stated Not compared
27 2 Single UK center* CR>1 23 Not stated 35% 120 10-y DFS
26%
Not compared Not stated Not compared
Purged  unpurged autologous BMT
28,29 2 Single US center Total 89†
CR1 10
CR2 27
CR>3 25
Relapse 27
28.1 (2-45)
18.3 (4-44)
12 (2-46)
19 (6-47)
Overall
30%
15%
16%
22%
42 2-y DFS
50%
21%‡
21%‡
0%
Not stated Not stated Not compared
ALL indicates acute lymphoblastic leukemia; BMT, bone marrow transplantation; CR1, ﬁrst complete remission; CR2/3, second or third complete remission; CR1, ﬁrst or greater complete remission;
CR2, second or greater complete remission; CR3, third or greater complete remission; DFS, disease-free survival; EFS, event-free survival; LFS, leukemia-free survival; OS, overall survival; UK,
United Kingdom.
*There is some overlap between reference 27 and 18.
†Fifty patients received purged and 39 patients received unpurged marrow, but results are presented for both groups together.
‡DFS was given for CR2 and CR3 groups combined.
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1nduction therapy regimen: the UK NE ALL III trial
nd were in CR1 at time of BMT [23]. All patients
eceived Mel and TBI as conditioning regimen with
o TRM. At a median follow-up of 3 years, the DFS
or the 13 patients in CR1 was 48%.
urged Autologous BMT
Abdallah et al. [24] reported the long-term fol-
ow-up of 32 adult (13 years) patients with ALL
reated with autologous purged BMT between 1984
nd 1994 at a single German center. Marrow was
urged with mafosfamide (n  25) or by in vitro
mmunomagnetic bead purging with a panel of mono-
lonal antibodies (n 7; anti-CD10, anti-CD19, anti-
D20, anti-HLA-DR). All patients received the same
nduction regimen according to the German Multi-
entre ALL (GM-ALL) trial [25]. At time of trans-
lantation, all patients were either in CR2 or greater
CR2) or were considered high risk by having one of
he following poor prognostic factors: older than 35
ears; WBC greater than 30  109/L at diagnosis;
ull-ALL phenotype; or failure to achieve CR1 within
weeks of treatment. Of 32 patients, 12 were in
ontinuous CR at a median follow-up of 143 months
range: 66-181 months) postautologous BMT; the
FS and OS rates were both 37.5%.
Gilmore et al. [26] presented the results of 27
atients with ALL (78%  16 years) treated in CR1
ith a purged autologous BMT at a single United
ingdom center between 1983 and 1989. Patients
eceived Cy and TBI (1500 cGy in 2 fractions, n 21)
r Ara-c, Cy, and TBI (1500 cGy in 2 fractions, n 
) as the conditioning regimen. Harvested marrow
as purged with anti-T- (anti-CD67) or anti-B- (anti-
D10  anti-CD19) cell monoclonal antibodies. At a
edian follow-up of 3.4 years, the DFS was 32%.
Mehta et al. [27] reported the long-term follow-up
f 23 patients with ALL (52%  15 years) treated in
R1 (n  11) or CR2 to fourth CR (n  12) with a
urged autologous BMT at a United Kingdom center
rom 1984 to 1986. Harvested marrow was purged in
itro with Campath-1 (anti-CD52) antibodies. All pa-
ients received Mel and TBI (850-1150 cGy in a single
raction) as the conditioning regimen. At a median
ollow-up of 10 years, the 10-year DFS was 26% and
he 10-year probability of relapse was 51%.
urged and Unpurged Autologous BMT
Doney et al. [28,29] retrospectively analyzed 89
onsecutive patients with ALL (50% age 16 years)
reated with an autologous BMT from 1979 to 1991 at
single US center. Marrow was purged with 4-hy-
roperoxycyclophosphamide (n  2), purged with
onoclonal antibodies (n  48), or was unpurged (n
39). Remission status at time of BMT was 10 CR1,7 CR2, 25 greater than CR2, and 27 relapse. Median 1
0uration of CR1 was 15.9, 24, and 24.7 months for the
R2, CR2, and relapse groups, respectively. Sites of
xtramedullary disease at relapse were CNS (n  28),
NS and testes (n 7), or other (n 15). All patients
eceived TBI-based conditioning regimens, with TBI
oses ranging from 1000 to 1575 cGy. Median fol-
ow-up time was not stated. The 2-year DFS was 50%
n the CR1, 21% in the CR2, and 0% in the relapse
roups, respectively (P not stated). A lower relapse
ate was associated with a lower WBC at diagnosis,
MT in CR1, and BMT given while not in relapse.
ELATED DONOR ALLOGENEIC BMT IN ADULT ALL
Table 6 summarizes the grading criteria, study
opulations, patient characteristics, and outcomes
rom adult studies included in the Related Donor
llogeneic BMT section. Evidence in this section is
aken from self-described studies of adult populations,
ll of which included patients at least 13 years of age.
vidence is presented with the highest quality studies
rst; studies of equal quality are presented in descend-
ng order with the largest sample size ﬁrst.
Ringden et al. [30], as part of a larger study exam-
ning acute leukemia outcomes, compared the results
f 826 adult (16 years) patients with ALL treated with
LA–identical related allogeneic BMT to 345 adult
16 years) patients with ALL treated with HLA–
dentical related allogeneic PBSCT reported to the
uropean Group of Blood and Marrow Transplant
EBMT) registry between 1994 and 2000. Of the
MT recipients, 62% were in CR1 at time of trans-
lantation, 18% were in CR2, and 20% had more
dvanced disease. The corresponding numbers for the
BSCT recipients were CR1 55%, CR2 20%, and
ore advanced 25%. In all, 9% of the BMT and 17%
f the PBSCT donor grafts were T-cell depleted.
BI-based conditioning regimens were used in 82%
f the BMT and 69% of the PBSCT groups. Engraft-
ent was signiﬁcantly faster in the PBSCT group
mean time to neutrophil recovery: 14 versus 19 days;
 .0001). By multivariate analysis, there was no
igniﬁcant difference between the BMT and PBSCT
roups with regard to acute or chronic GVHD, TRM,
FS, or OS. The only signiﬁcant multivariate risk
actors for improved LFS and OS were disease status
t transplantation (CR1  CR2  advanced disease)
nd MTX-containing immunosuppression for GVHD
rophylaxis.
Passweg et al. [31] assessed the impact of immu-
ophenotype on risk of relapse and GVHD. Recipi-
nts of 1132 BMTs from HLA–matched siblings in
R1 (n  605) or CR2 (527) for T-lineage (n  416)
r cALLa B precursor (B-lineage) (n  716) ALL
eported to the IBMTR between 1982 and 1992 by
65 centers were studied. Median duration of CR1
Table 6. Comparison of Patient Characteristics and Outcomes from the Articles in the Related Donor Allogeneic Stem Cell Transplantation Section
Reference
Quality and
Strength of
Evidence
Patient
Populations No. of Patients
Median (range)
Age at Time of
Transplant
Treatment-
Related
Mortality
Median
Follow-Up
(mos) LFS/EFS/DFS
Significance
LFS/EFS/DFS OS
Significance
OS
30 2 EBMT registrya Total 1171
BMT 826
PBSCT 345
28 (16-60)b
31 (16-62)b
Overall
23%c
23%c
25b
14b
Overall LFS
59%c
46%c
Not significant Overall
63%c
57%c
Not significant
31 2 IBMTRd Total 1132
T lineage 416
B lineage 716
20 (1-49)e
23 (1-52)e
Not stated Not stated Not statedf P < .05f Not stated Not compared
32 2 EBMT registrya Total 790
BMT < 1986 248
BMT > 1986 542
21 (1-43)
23 (1-51)
3 y
39%
25%
93
38
3-y LFS
45%
54%
P  .004 Not stated Not compared
33 2 EBMT registrya Total 772g
CR1 430 24 (1-52)
2 y 2-y LFS
cGVHD 110 13% Not stated 77% P  .0005
No cGVHD 236 13% 60%
CR>2/Rlps1 342 14 (1-48)
cGVHD 62 35% 44% Not significant Not stated Not compared
No cGVHD 204 12% 54%
34 2 Single US center Total 605
Donor/patient
sex F/F 121
M/F 93
F/M 186
M/M 205
33 (1-72)h
32 (1-64)h
32 (1-70)h
33 (1-68)h
Not stated Not stated Not stated P  .07i Not stated P  .09i
35 2 IBMTR twins
vs. sibsd
Total 264
Identical twins 24
Matched sibs 240
17 (1-30)
17 (1-36)
3 y
10%
21%
65
60
3-y LFS
57%
58%
Not significant Not stated Not compared
36 2 IBMTR Ph ALL Total 67
CR1 33
CR2/Rlps 22
PIF 12
28 (5-49) 2 y
42%
40%
42%
36 2-y LFS
38%
42%
25%
Not compared Not stated Not compared
37 2 2 US centers CR1 53 24 (<1-45) Overall
26%
66 5-y DFS
61%
Not compared 5 y
61%
Not compared
38 2 10 French centers CR1 42 25.9 (3-41)b Overall
38%
66 7-y EFS
40%
Not compared 7-y
45%
Not compared
39 2 IBMTR PIF 38 32 (1-50) 3 y
44%
41 3-y LFS
23%
Not compared Not stated Not compared
40 2 Single US centerj CR1 34 27.8 (1-45) Overall
29%
24 3-y DFS
64%
Not compared Overall
65%
Not compared
41 2 Single US center CR1 55k 24 (0-48) Overall
22%
72 10-y EFS
64%
Not compared 10-y
66%
Not compared
42 2 Single Korean
center Ph ALL
Total 23
CR1 14
CR2 9
36 (15-44) 2 y
27.8%
24 2-y DFS
43.5%
Not compared Not stated Not compared
43 2 IBMTR Total 634
CR1 243
CR2 391
Not stated
(16-not stated)
Not stated
(not stated)
Not stated 21 Not statedl Not compared Not stated Not compared
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Table 6. Continued
Reference
Quality and
Strength of
Evidence
Patient
Populations No. of Patients
Median (range)
Age at Time of
Transplant
Treatment-
Related
Mortality
Median
Follow-Up
(mos) LFS/EFS/DFS
Significance
LFS/EFS/DFS OS
Significance
OS
44 2 Single US center Total 43 Not stated
(9-51)
Overall
26%
106 Not statedm Not compared Not statedm Not compared
45 2 Single Canadian
center
Total 40
BuCy 29
BuCyVP 11
23 (2-49)
16 (1-39)
2 y
24%
27%
33 3-y DFS
39.9%
45.5%
Not significant Not stated Not compared
46 2 Single US center CR1 39 23 (16-41)n Overall
23%
18 Overall DFS
63%
Not compared Not stated Not compared
47 2 Single UK center CR1 32 23 (7-41) 3 mo
22%
50 Overall DFS
50%
Not compared Not stated Not compared
48 2 Single Spanish
center
Total 30
CR1/2 17
CR>3 13
17 (5-36)
16 (6-33)
1 y
18%
15%
48 5-y DFS
69.5%
15.4%
P < .01 Not stated Not compared
49 2 Single Hong Kong
center
CR>1 or Rlps>1
29
31 (15-43) Day 100
10%
38 3-y DFS
40%
Not compared Not stated Not compared
50 2 Single Australian
center
Total 27
CR1 13
Rlps>1, CR>2 14
20 (15-42)
21 (14-52)
Overall
32.5%o
42.5%o
Not stated Overall DFS
86%
28%
Not compared Overall
48%
21%
P  .06
51 2 Single Italian
center
Total 24
CR1/2 17
Rlps 7
23 (6-49) Overall
17.6%
14.3%
92
66
Overall EFS
59%
14%
Not compared Not stated Not compared
52 2 Single US center
Ph ALL
CR1 23p 30 (6-44) Day 100
26%
40 3-y DFS
65%
Not compared Not stated Not compared
ALL indicates acute lymphoblastic leukemia; BMT, bone marrow transplantation; Bu, busulfan; cGVHD, chronic graft-versus-host disease; CR1, ﬁrst complete remission; CR2, second complete
remission; CR1/2, ﬁrst or second complete remission; CR1; ﬁrst or greater complete remission; CR2, second or greater complete remission; CR3, third or greater complete remission; Cy,
cyclophosphamide; DFS, disease-free survival; EBMT, European Group for Blood and Marrow Transplant; EFS, event-free survival; F, female; IBMTR, International Bone Marrow Transplant
Registry; LFS, leukemia-free survival; M, male; OS, overall survival; PBSCT, peripheral blood stem cell transplantation; Ph, Philadelphia Chromosome positive; PIF, primary induction failure;
Rlps, relapse; Rlps1, ﬁrst relapse; Rlps1, ﬁrst or greater relapse; sibs, siblings; VP, VP-16/etoposide; UK, United Kingdom.
aThere is some overlap between references 30, 32, and 33.
bMean instead of median was given in article.
cIn CR1 patients only, in CR2 patients TRM was 29% (BMT) and 25% (PBSCT), in advanced disease patients. TRM was 55% (BMT) and 45% (PBST).
dThere is some overlap between the patients included in reference 31 and 35.
eData are given for the 273 T-lineage and 332 B-lineage ALL patients who underwent transplantation in CR1. The results for the 143 T-lineage and 384 B-lineage ALL patients who underwent
transplantation in CR2 were similar.
fMultivariate analysis of relapse risk showed a signiﬁcant risk reduction in those who developed GVHD in both T-lineage ALL (RR  0.34; P  .005) and B ALL (RR  0.44; P  .002) transplanted
in CR1 and in T-lineage ALL (RR  0.54; P  .05) and B-ALL (RR  0.61; P  .01) transplanted in CR2; LFS, EFS, DFS, OS, TRM, and median follow-up time were not stated in the article.
gPatients had to be alive at 3 months post-BMT without relapse to be included in this group.
hIncludes patients with ALL, AML, CML, HD, NHL, MDS, MM, and other hematologic malignancies.
iBased on the hazard ratio of risk of relapse or survival. EFS/DFS/OS were not stated for any groups.
jThere is some overlap with reference 37.
kIncludes 39 adult (18 y) and 16 pediatric (18 y) patients.
lRelapse risk is stated comparing methotrexate-treated vs. cyclosporine or T-cell depletion-treated patients; DFS/RFS were not stated.
mOS and RFS curves are presented but the rate at any given time point was not stated.
nWith the exception of one infant included in the study population.
oRate is given for both the AML (n  42) and ALL (n  27) patients together.
pFour patients were also included in reference 40.
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Cytotoxic Therapy with SCT for Adult ALL
Bas 12 versus 28 months for the patients with T-
ersus B-lineage ALL in CR2 (P  .0001). Sites of
rior relapse were not stated. There was no difference
n the incidence or severity of acute or chronic
VHD between the T- and B-lineage ALL groups
hen stratiﬁed by CR1 versus CR2. There was a
igniﬁcantly lower risk of relapse in patients who did
ersus did not develop GVHD, which was seen in
oth the T- and B-lineage groups stratiﬁed by CR1
ersus CR2 (T-ALL in CR1 relative risk [RR]  0.34,
 .005; B-ALL in CR1 RR  0.44, P  .002;
-ALL in CR2 RR  0.54, P  .05; B-ALL in CR2
R  0.61, P  .01).
Frassoni et al. [32] assessed the impact of year of
MT on TRM, LFS, and relapse rate in 790 adult and
ediatric patients with ALL treated with an HLA–
atched related allogeneic BMT in CR1 and reported
o the EBMT registry between 1979 and 1991. Pa-
ients treated before 1986 (n  248, median age 21
ears) were compared with those treated in 1986 or
ater (n  542, median age 23 years). Patients treated
ince 1986 had a signiﬁcantly shorter follow-up time
P  .001), fewer TBI-containing conditioning regi-
ens (P  .001), more patients receiving CSA and
TX for GVHD prophylaxis compared with either
gent alone (P  .0001), a shorter interval from diag-
osis to BMT (P  .0004), and a lower incidence of
hronic GVHD (P  .003). There was a marginally
igher median age at BMT in the 1986 and later
roup (23 versus 21; P  .07). TRM at 3 years was
igniﬁcantly lower in patients who underwent trans-
lantation since 1986 compared with earlier (25%
ersus 39%; P  .0001); correspondingly, LFS in-
reased from 45% before 1986 to 54% since 1986
P  .004). The relapse incidence did not change over
ime. Signiﬁcant multivariate prognostic factors for
igher TRM were older age (measured as a continu-
us variable in all analyses; P  .0001), female donor
o male recipient (P  .008), and year of BMT (mea-
ured as a continuous variable in all analyses; P 
0001). Signiﬁcant multivariate prognostic factors for
mproved LFS were year of BMT after 1986 (P 
0001) and younger age at BMT (P  .0001).
Ringden et al. [33] assessed the impact of acute
nd chronic GVHD on relapse rate, TRM, and LFS
n 772 adult and pediatric patients with ALL treated
ith an HLA–matched sibling allogeneic BMT in
R1 (n  430, median age 24 years) or CR2/ﬁrst
elapse (n  342, median age 14 years) between 1987
nd 1993 and reported to the EBMT by 89 centers.
ites of prior relapse and duration of CR1 were not
tated. All patients received CSA and MTX for
VHD prophylaxis. There was a signiﬁcant decrease
n relapse rate and LFS with a corresponding signiﬁ-
ant increase in TRM for both groups with increasing
rade of acute GVHD. For patients who underwent
ransplantation in CR1, the relapse rate was signiﬁ- P
B&MTantly lower (P  .0001) and the 2-year LFS was
igniﬁcantly better in patients who developed chronic
VHD compared with those who did not. In the
ore advanced disease group, there was no signiﬁcant
ifference in the relapse rate or 2-year LFS but a
igniﬁcantly higher TRM rate in the patients who
eveloped chronic GVHD compared with those who
id not.
Randolph et al. [34] compared the risk of relapse
y donor-recipient sex in 3238 patients with hemato-
ogic malignancies treated with an HLA–matched re-
ated donor at a single US center from 1969 to 2001.
dult (median age 33 years) patients with ALL (n 
05) who received a female/female (n  121), male/
emale (n  93), female/male (n  186), or male/male
n  205) donor/recipient related allogeneic SCT
ere included if they expressed at least one class I
LA allele from the following: HLA-A1, A2, A3, B7,
8, B40, or B60. These alleles were chosen because
hey are the most common in the North American
opulation and present at least one of the deﬁned H-Y
ntigens. It is not stated how many patients were HLA
yped by serologic versus molecular methods. Condi-
ioning regimens and GVHD prophylaxis regimens
ere not stated for patients with ALL, but were TBI-
ontaining in 74% and CSA and MTX in 45% of all
atients, respectively. In patients with ALL, male
CT patients with female donors had a trend toward
lower risk of relapse compared with other donor/
ecipient sex categories (hazard ratio  0.77, adjusted
or patient and donor age, GVHD prophylaxis, dis-
ase status, conditioning regimen, and patient/donor
ytomegalovirus status; P .07). Male SCT recipients
ith female donors also had a trend toward an in-
reased risk of death compared with other categories
hazard ratio  1.18, controlling for the same factors as
isk of relapse. P  .09).
Gale et al. [35] performed a matched case control
tudy of 24 identical twin BMTs for ALL in CR1 treated
etween 1978 and 1990 reported to the IBMTR by 66
enters with 240 HLA–matched sibling donor BMTs
or ALL in CR1 selected from 581 BMTs reported by
63 centers to the IBMTR during the same time
eriod. Donor-recipient sex matching and GVHD
rophylaxis signiﬁcantly differed between the groups
ut could not be matched on. Factors including age at
MT, WBC at diagnosis, immunophenotype, and
ime to CR1 were compared by univariate analysis for
igniﬁcant differences to determine factors used for
atching; only age at BMT was signiﬁcant and used
o match case and control subjects. BMT recipients
rom identical twins had a higher 3-year relapse rate
36% versus 26%; P  .1) and lower 3-year TRM
10% versus 21%; P .1) compared with the matched
ibling BMT group. There was no difference in 3-year
FS between the two groups (57% versus 58%;
 .2).
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1Barrett et al. [36] analyzed the outcomes of 67
atients with Ph ALL (81%  16 years old) treated
ith an HLA–matched sibling BMT and reported to
he IBMTR between 1978 and 1990. Ph was the
nly karyotypic abnormality in 45 patients (67%),
hereas 22 patients (33%) had the Ph with other
aryotypic abnormalities. Conditioning and GVHD
rophylaxis regimens varied by reporting center; how-
ver, 72% of patients received a TBI-containing con-
itioning regimen. At a median follow-up of 36
onths, 33 patients who underwent transplantation in
R1 had a 2-year LFS of 38% versus 41% in 22
atients with relapse and 25% in 12 patients with
rimary induction failure.
A subset analysis compared the 33 patients with
R1 and Ph ALL with 33 matched control patients
elected from 106 patients with Philadelphia chromo-
ome–negative ALL reported to the IBMTR during
he same time period and who underwent transplan-
ation in CR1. Control patients were matched on age
t diagnosis, WBC at diagnosis, and time from diag-
osis to transplantation; other patient characteristics
ere not signiﬁcantly different between case and con-
rol subjects. Patients with Ph ALL tended to have
arlier relapses (34% versus 23% at 2 years) and lower
-year LFS (38% versus 49%) compared with the
hiladelphia chromosome–negative ALL matched
ontrol patients; however, these differences were not
tatistically signiﬁcant.
Chao et al. [37] presented the results of 53 patients
ith high-risk ALL (95%  16 years old) treated in
R1 with an HLA–matched sibling BMT at two US
enters. High risk was deﬁned as having one of the
ollowing factors: WBC 25,000/L or higher at diag-
osis; cytogenetic abnormalities (t(4;11), t(8;14), or
(9;22)); age 30 years or older; extramedullary disease;
nd longer than 4 weeks to achieve CR1. Condition-
ng regimens were Ara-c, Cy, and TBI (1000 cGy in a
ingle dose, n  17), Cy and TBI (1320 cGy fraction-
ted, n  17), or etoposide (VP) and TBI (1320 cGy
ractionated, n  19). GVHD prophylaxis regimens
onsisted of MTX and prednisone, CSA and pred-
isone, or CSA, MTX, and prednisone. At a median
ollow-up of 5.5 years, the 5-year OS and DFS were
oth 61%. A multivariate analysis of prognostic fac-
ors indicated an improved DFS with male sex (P 
016), younger age (P  .003), and shorter time to CR
P  .014).
Deconinck et al. [38] reported the results of 42
atients with ALL (88%  15 years old) treated with
n HLA–matched sibling allogeneic BMT in CR1 at
0 French centers from 1987 to 1991. All patients
eceived Ara-c, Mel, and TBI (1000 cGy as single dose
n 14 patients or 1200 cGy in 6 fractions in 28 pa-
ients) as conditioning regimen. GVHD prophylaxis
onsisted of CSA and MTX (n  39), CSA and MP (n2), or T-cell depletion (n  1). At a median fol- a
4ow-up of 66 months, the 7-year OS and EFS rates
ere 45% and 40%, respectively.
Biggs et al. [39] analyzed 38 patients with ALL
8%  10 years old, 45%  19 years old) treated with
n HLA–matched sibling allogeneic BMT after failing
o achieve CR1 with two or more courses of induction
hemotherapy and reported to the IBMTR by 49
enters between 1982 and 1989. Conditioning regi-
ens were TBI-based in 83% of patients. GVHD
rophylaxis regimens varied by center. At a median
ollow-up of 41 months, the 3-year LFS was 23%
95% conﬁdence interval, 12%-40%). LFS was signif-
cantly higher in patients 30 years compared with
30 at time of BMT (37% versus 9%; P  .02). The
-year probability of TRM was signiﬁcantly lower in
atients 30 years compared with 30 at time of
MT (13% versus 80%; P  .004).
Snyder et al. [40] described the outcomes of 34
atients with ALL (79%  20 years old) treated with
n HLA–matched related allogeneic BMT between
986 and 1992 at a single US center. All patients
eceived VP and TBI (1320 cGy in 11 fractions) for
onditioning, and CSA and MP (n 15) or CSA, MP,
nd MTX (n  19) for GVHD prophylaxis. At a
edian follow-up of 24 months, the 3-year DFS was
4%. The 3-year DFS was improved in patients
ounger than 20 years versus 20 years or older at time
f BMT (100% versus 54%; P  .05).
Jamieson et al. [41] reported the results of a ret-
ospective analysis of 85 pediatric and adult patients
ith ALL treated in CR1 or CR2 with an HLA–
atched sibling allogeneic BMT at a single US center
etween 1987 and 2002. The majority of patients
71%) treated in CR1 (n  55) were adults and their
esults are presented here. The majority of patients
83%) with CR2 (n  30) were younger than 18 years
nd were presented in the pediatric ALL review [3].
ll patients received VP and TBI (1350 cGy in 11
ractions). GVHD prophylaxis consisted of CSA and
rednisone; CSA, MTX, and prednisone; or CSA and
TX. At a median follow-up of 6 years, the 10-year
FS was 64% and the 10-year OS was 66%.
Lee et al. [42] reported the results of 23 adult (15
ears) patients with Ph ALL treated with an HLA–
atched related allogeneic BMT at a single Korean
enter between 1996 and 2001. Patients underwent
ransplantation in CR1 (n  14) or CR2 (n  9).
edian CR1 duration and sites of prior relapse were
ot stated for the patients with CR2. Conditioning
egimen consisted of Cy and TBI (1329 cGy) for
atients with CR1 and Ara-c, Mel, and TBI (1200
Gy) for patients with CR2. GVHD prophylaxis con-
isted of CSA and MTX. At a median follow-up of 24
onths, the 2-year DFS was 43.5%. Eight patients
ad bone marrow samples taken before and after
MT and analyzed by reverse-transcription polymer-
se chain reaction for BCR-ABL. The kinetics of BCR-
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Cytotoxic Therapy with SCT for Adult ALL
BBL correlated with development of chronic GVHD
nd remission status.
Horowitz et al. [43] reported on 634 adult and
ediatric patients with ALL treated in CR1 (n  243,
00%  16 years at time of BMT) or CR2 (n  391,
dults and children but no ages are stated) with an
LA–matched sibling BMT from 1978 to 1986 and
eported to the IBMTR. Median duration of CR1 and
ites of prior relapse were not stated. At a median
ollow-up of 21 months, the 5-year relapse rate for
dults in CR1 who received MTX  MP for GVHD
rophylaxis was 10% compared with 50% for adults
eceiving no MTX (P  .0003). For adult and pedi-
tric patients who underwent transplantation in CR2,
he 5-year relapse rate in MTX-containing GVHD
rophylaxis was 43% versus 65% in CSA-based regi-
ens or T-cell depletion (P  .0001).
Kumar et al. [44] retrospectively reviewed 43 pa-
ients with ALL (median age  25 years) treated with
n HLA–matched (n  37) or 1-antigen mismatched
n  6) related BMT at a single US center between
982 and 1999. Twenty-two patients were treated in
R1; all others had advanced (not speciﬁed) disease.
he median CR1 duration and sites of prior relapse
ere not stated for the patients with advanced disease.
onditioning regimen consisted of Cy and TBI (1320
Gy, n  28); VP, Cy, and TBI (1320 cGy, n  13);
r other (not speciﬁed, n  2). GVHD prophylaxis
onsisted of CSA and MTX (n  28); MTX alone (n
6); CSA and prednisone (n  4); CSA, MTX, and
rednisone (n  3); or other (n  2). The 15 patients
hose day21 absolute lymphocyte count was 175 
06/L or less had a signiﬁcantly lower relapse-free
urvival and OS than the 28 patients whose absolute
ymphocyte count was more than 175  106/L (P 
0028 and .0275, respectively). Survival rates were not
tated in the article. Multivariate analysis determined
hat the day21 absolute lymphocyte count 175 
06/L (RR 4.5; P  .022) and no chronic GVHD (RR
2.1; P  .0006) were signiﬁcant independent risk
actors for relapse.
von Bueltzingsloewen et al. [45] compared two
on-TBI-containing conditioning regimens in 40
onsecutive patients with ALL (73%  15 years old)
reated with a related allogeneic BMT from 1987 to
991 at a single Canadian center. Remission status at
ime of BMT was 23 CR1, 11 CR2, 4 CR3, and 2
R4. Median duration of CR1 and sites of prior re-
apse were not stated. Thirty-four patients had an
LA–matched, 4 patients had a single antigen mis-
atch, 1 patient a 2-antigen mismatch, and 1 a syn-
eneic donor. Conditioning regimens consisted of
usulfan (Bu) and Cy (n 29) or Bu, Cy, and VP (n
1). GVHD prophylaxis consisted of CSA and MTX
n  36); MTX and MP (n 1); CSA, MTX, and MP
n  1); MTX alone (n  1); or nothing (n  1
yngeneic). At a median follow-up of 33 months, the n
B&MT-year DFS was not signiﬁcantly different between the
onditioning regimen groups (39.9% Bu and Cy ver-
us 45.5% Bu, Cy, and VP; P  .72).
Blume et al. [46] evaluated 39 patients with ALL
38 patients were  16 years old, 1 infant was also
ncluded) treated in CR1 with an HLA–identical re-
ated allogeneic BMT at a single US center between
979 and 1985. Conditioning regimens were Ara-c,
y, and TBI (1000 cGy, single fraction) (n  18) and
y and TBI (1320 cGy, fractionated) (n  21). For
VHD prophylaxis, 28 patients received MTX and
rednisone and 11 patients received CSA and pred-
isone. One patient received a second related alloge-
eic BMT for leukemia recurrence. At a median fol-
ow-up of 18 months, the DFS was 63%.
McCarthy et al. [47] reported 32 consecutive pa-
ients with ALL (72%  16 years old) in CR1 treated
ith a HLA–matched related donor BMT at a single
nited Kingdom center from 1978 to 1987. Condi-
ioning regimens consisted of vincristine, pred-
isolone, Cy, and TBI (950-1050 cGy in a single
raction, n  20); vincristine, prednisolone, Ara-c,
eniposide (VM26), daunorubicin, and TBI (1050 cGy
n a single fraction, n  4); vincristine, prednisolone,
ra-c, VM26, and TBI (1300 cGy in two fractions, n
5); or not stated (n  3). GVHD prophylaxis con-
isted of CSA alone (n  21); T-cell depletion with
ampath-1 and CSA (n  6); T-cell depletion with
ampath-1 alone (n 4); or MTX alone (n 1). Risk
actors for BMT in CR1 included older than 16 years
t diagnosis, WBC greater than 25  109/L, null or
-lineage disease, chromosomal translocations, or
NS disease. Patients had 1 (n  21), 2 (n  11), or
(n  1) risk factors. Day 100 TRM was 22%. At a
edian follow-up of 50 months, DFS was 50%.
De la Camara et al. [48] studied 30 consecutive adult
nd pediatric patients with high-risk ALL (63%  15
ears old) treated with an HLA–matched sibling BMT
including one identical twin) from 1983 to 1990 at a
ingle Spanish center. High risk was deﬁned as re-
apsed ALL (CR2 or ﬁrst relapse) or the presence of
ne of more of the following in patients with CR1: 15
ears or older at time of diagnosis; WBC greater than
r equal to 100  109/L; longer than 7 weeks to
chieve CR1; L3 or B mature immunophenotype;
(9;22) or t(8;14); or CNS disease. Cy and TBI was
sed as conditioning regimen in 87% of patients; CSA
nd MTX was used as GVHD prophylaxis in 67%. At
median follow-up of 4 years, the 5-year DFS was
igniﬁcantly higher in the CR1 and CR2 groups (n 
7) versus the greater than CR2 group (n  13)
69.5% versus 15.4%; P  .01).
Au et al. [49] reported 29 consecutive adult (15
ears) patients with ALL treated with HLA–identical
elated allogeneic BMT in CR1 (n  12) or ﬁrst or
reater relapse (Rel1)/CR2 (n  17, CR2 n  9,
ot in CR n  8) between 1990 and 1997. Condition-
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1ng regimens included Cy and TBI (1200 cGy, n 
5); VP, Cy, and TBI (1200 cGy, n  12); Bu and Cy
n  1); and Cy, carmustine (BCNU), and VP (n 
). CSA and MTX was used for GVHD prophylaxis.
t a median follow-up of 38 months, the 3-year
FS was 40%.
Atkinson et al. [50] compared 41 adult (14 years)
atients (acute myeloid leukemia [AML] n  28, ALL
 13) treated with an HLA–matched sibling donor
llogeneic BMT in CR1 with 28 adult patients (AML
 14, ALL n  14) treated with an HLA–matched
ibling donor in CR2 or Rel1 at a single Australian
enter between 1981 and 1985. An additional 6 pa-
ients had primary refractory disease and one patient
as treated as initial therapy. All patients received Cy
nd TBI (1200-1400 cGy) as the conditioning regi-
en and CSA (n  59) or MTX (n  17) as GVHD
rophylaxis. Posttransplantation therapy was given for
eukemia recurrence and consisted of conventional
hemotherapy (n  13) or a second transplantation (n
4) using the same donor and GVHD prophylaxis
egimen but using Cy and Mel as the conditioning
egimen. The 42-month OS was 48% for the ALL
R1 group versus 21% for the ALL Rel1/CR2
roup (P .06). The DFS, censoring all deaths caused
y transplantation-related complications, was 86% for
he ALL CR1 group versus 28% for the ALL Rel1/
R2 group (P not stated). At 12 months posttrans-
lantation, the median Karnofsky performance score
as 100% (range: 70%-100%) in the group that un-
erwent transplantation in CR1 and 100% (range:
0%-100%) in those who underwent transplantation
n Rel1/CR2.
Aversa et al. [51] studied an alternative condition-
ng regimen in 24 adult and pediatric patients with
LL (67%  18 years old) treated with an HLA–
atched related allogeneic BMT in CR1 (n  7), CR2
n  10), or relapse (n  7) from 1989 to 1993 at a
ingle Italian center. Five patients had a history of
xtramedullary disease. The median duration of CR1
as 8 months. The conditioning regimen consisted of
hiotepa, Cy, and TBI (1440 cGy) and antithymocyte
lobulin (ATG) in all patients. GVHD prophylaxis
onsisted only of ex vivo T-cell depletion by soybean
gglutination and (sheep red blood cell) E-rosetting.
here were no cases of graft failure or acute or
hronic GVHD. Seventeen patients underwent trans-
lantation in CR1 or CR2 with an EFS of 59% at a
edian follow-up of 7.7 years. Seven patients under-
ent transplantation in Rel1 with an EFS of 14% at
median follow-up of 5.5 years.
Snyder et al. [52] reported the results of 23 pa-
ients with Ph ALL (1 patient  18 years old)
reated with an HLA–matched sibling allogeneic
MT in CR1 between 1984 and 1997 at a single US
enter. Patients received VP and TBI (1320 cGy in 11
ractions) (n  21); VP, Cy, and TBI (n  1); or Cy t
6nd TBI (n  1) as conditioning regimen. GVHD
rophylaxis consisted of CSA, MTX, and MP (n 
2); CSA and MP (n  8); or CSA and MTX (n  3).
t a median follow-up of 40 months, the 3-year DFS
as 65%.
NRELATED DONOR ALLOGENEIC BMT IN
DULT ALL
Table 7 summarizes the grading criteria, study
opulations, patient characteristics, and outcomes
rom adult studies included in the Unrelated Donor
llogeneic BMT section. Evidence in this section is
aken from self-described studies of adult populations,
ll of which included patients at least 13 years of age.
vidence is presented with the highest quality studies
rst; studies of equal quality are presented in descend-
ng order with the largest sample size ﬁrst.
Cornelissen et al. [53] reported the results of 127
dult (16 years) patients with ALL who received a
atched (n  78) or single antigen mismatched (n 
9) unrelated BMT through the National Marrow
onor Program between 1988 and 1999 at 46 centers.
ll patients were at poor risk deﬁned as the presence
f t(9;22) (n  97), t(4;11) (n  25), or t(1;19) (n  5).
atients underwent transplantation in CR1 (n  64),
R2 or CR3 (n 16), or after primary induction or in
elapse (PIF/Rel, n  47). Conditioning regimens
ere TBI-based in 115 patients and chemotherapy
lone in 12 patients. Thirty-three patients received
-cell depleted grafts. Primary graft failure occurred
n 6% of patients. By multivariate analysis, risk factors
or worse DFS were BMT in PIF/Rel (RR  2.85;
 .0001), longer interval from diagnosis to BMT
RR  1.33; P  .008), and HLA–mismatched donor
RR  1.76; P  .02). The presence of t(9;22) dem-
nstrated a signiﬁcant DFS advantage (RR  0.49; P 
006).
Gaderet et al. [54] compared the outcomes of
BSCT versus BMT in patients with ALL (n  102)
r AML (n  111) treated with an unrelated alloge-
eic transplantation between 1994 and 1999 and re-
orted to the EBMT Acute Leukemia Registry. Of the
atients with ALL, 58% were older than 16 years at
ime of transplantation. Of the patients with ALL, 19
19%) underwent transplantation in CR1, 54 (53%) in
R2 or CR3, and 29 (28%) in other disease stages.
BSCT recipients were matched with a historic group
f BMT recipients on the following: disease status at
ransplantation, patient age, year of transplantation,
nd T-cell depletion. There was no information on
BC at diagnosis, immunophenotype, CR1 duration,
r sites of prior relapse. At a median follow-up of 16
nd 23 months in the PBSCT and BMT groups,
espectively, the 2-year LFS was signiﬁcantly lower in
he patients with ALL treated with PBSCT versus
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Cytotoxic Therapy with SCT for Adult ALL
BMT (21% versus 32%; P  .04). The 2-year OS was
lso signiﬁcantly lower for the PBSCT group (34%
ersus 24%; P  .04). Multivariate analysis indicated
BSCT was a risk factor for decreased LFS and OS,
nd CR at transplantation was associated with an in-
reased LFS and OS.
Sierra et al. [55] presented the outcomes of 18
atients with Ph ALL who underwent HLA–
atched unrelated allogeneic BMT from 1988 to
995 at a single US center. Of 18 patients, 3 (17%)
ere younger than 18 years at time of BMT. Disease
tatus at time of BMT was CR1 (n  7), CR2 (n  1),
elapse 1 (n  3), or refractory disease (n  7). All
atients received Cy and TBI for conditioning and
TX and CSA or tacrolimus as GVHD prophylaxis.
t a median follow-up of 17 months, 5 patients had
ecurrent disease and died of disease, whereas 4 died
f treatment-related causes. LFS at 2 years was 49%.
ELATED AND UNRELATED DONOR ALLOGENEIC BMT
N ADULT ALL
Table 8 summarizes the grading criteria, study
opulations, patient characteristics, and outcomes
rom adult studies included in the Related and Unre-
ated Donor Allogeneic BMT section. Evidence in
his section is taken from self-described studies of
dult populations, all of which included patients at
east 13 years of age. Evidence is presented with the
ighest quality studies ﬁrst; studies of equal quality are
resented in descending order with the largest sample
ize ﬁrst.
Kiehl et al. [56] compared the outcomes of 221
onsecutive adult (17 years) patients with ALL
reated with an HLA–matched related (n  103) ver-
us unrelated (n  118) donor BMT at 9 European
enters from 1990 to 2002. Signiﬁcantly more patients
eceived a related versus unrelated allogeneic BMT in
R1 (60% versus 27%; P  .001). Overall, 33% of
atients had Ph ALL. Conditioning regimens con-
isted of Cy and TBI  other (n  65 related, 95
nrelated); Bu and Cy  other (n  15 related, 18
nrelated); VP and TBI (n  21 related, 0 unrelated);
r other combinations (n  3 related, 5 unrelated).
VHD prophylaxis consisted of CSA and MTX (n 
9 related, 69 unrelated); CSA and prednisone (n 27
elated, 6 unrelated); CSA, MTX, and prednisone (n
1 related, 21 unrelated); or other combinations (n
1 related, 22 unrelated). At a median follow-up of 7.1
onths, there was no signiﬁcant difference in the
-year DFS between related versus unrelated donor
llogeneic BMT in CR1 (42% versus 45%; P  not
tated) (Figure 5). There was a signiﬁcantly improved
-year DFS for TBI- versus Bu-based conditioning
egimens in all patients regardless of donor relation or
isease status at time of BMT (30% versus 17%; P .041).Ta Re AL *A
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1Cahn et al. [57] investigated the feasibility of per-
orming allogeneic BMT in 192 patients with acute
eukemia in CR1 older than 40 years reported to the
BMT registry. There were 41 patients with ALL
lder than 40 years in CR1 who were compared to 467
dult patients with ALL in CR1 aged 16 to 40 years
eported to the same registry. Patients in the two age
roups were not signiﬁcantly different on interval from
iagnosis to BMT, sex, French-American-British clas-
iﬁcation, sex match of the donor/recipient, or condi-
ioning regimen. The article does not state if the
onors were related, so it is assumed this study in-
ludes patients with both related and unrelated allo-
eneic BMT. The probability of TRM was higher in
he older age group (37% versus 28%; P  .09). The
robability of relapse at 4 years was 38% for the older
nd 29% for the younger age groups (P  .32). The
robability of 4-year OS was signiﬁcantly lower in the
lder age group (36% versus 54%; P  .03). Six
actors were selected for multivariate analysis: age, sex,
ex matching, conditioning regimen, acute GVHD
rophylaxis, and time from diagnosis to BMT; how-
ver, none of these were signiﬁcant independent pre-
ictors of OS or LFS.
Doney et al. [58] retrospectively analyzed the out-
omes of 182 adult (18 years) patients with ALL
reated with an allogeneic BMT in CR1 (n 41) CR2
n 46), or relapse (n 95) at two US centers between
990 and 1997. Allogeneic donors were HLA–
atched related (n  88), HLA–matched unrelated (n
33), HLA–mismatched related (n  26), or HLA–
ismatched unrelated (n  35). Conditioning regi-
ens consisted of Cy and TBI (1200-1575 cGy, n 
69), chemotherapy only (n  8), or chemotherapy
not Cy) and TBI (1320-1575 cGy, n  5). GVHD
rophylaxis consisted of CSA and MTX (n  105),
SA and MP  other (n  30), CSA alone (n  26),
r other (n  21). Median duration of CR1 and sites
f prior relapse for the patients with CR2 and re-
apse were not stated. At a median follow-up of 36
onths, the 5-year DFS was 21% for all patients.
atients who underwent transplantation in CR1 had a
igniﬁcantly (P  .001) better 5-year DFS (43%) than
hose who underwent transplantation in CR2 (23%)
r in relapse (9%). Multivariate analysis of risk factors
etermined age older than 40 years (RR  1.91; P 
01), transplantation in relapse (RR  3.46; P  .01),
nd GVHD prophylaxis with CSA alone (RR  1.96;
 .01) were signiﬁcant independent predictors of
ower DFS.
Esprou et al. [59] retrospectively analyzed 121
onsecutive patients with Ph ALL (84%  18 years
ld) treated with an allogeneic SCT on one of 3
rospective French trials at 27 centers between 1992
nd 2000. Patients underwent transplantation in CR1
n  76), CR2 (n  10), or with refractory disease
n  35). Allogeneic donors were HLA–matched re- B
8ated (n  87), identical twin (n  1), HLA–matched
nrelated (n  31), or HLA–mismatched related (n 
). Conditioning regimens consisted of VP, Cy, and
BI (1200 cGy in 6 fractions, n 48); Mel, Ara-c, and
BI (1200 cGy in 6 fractions, n  21); or various
ther regimens (n  52). GVHD prophylaxis con-
isted of CSA and MTX in all but 8 patients who
eceived T-cell depleted grafts. At a median follow-up
f 29 months, the 2-year OS was signiﬁcantly better
or patients who underwent transplantation in CR1
ompared with all others (50% versus 17%; P 
0001).
Stirewalt et al. [60] performed a retrospective
nalysis of 90 consecutive patients with Ph ALL
50%  33 years old) treated with an autologous (n 
), matched related donor (n  31), mismatched re-
ated donor (n  14), or matched unrelated donor
n  37) SCT at a single US center from 1989 to
001. Conditioning regimens were Cy and TBI
1200-1575 cGy, n  74); Cy, TBI, and ATG (1200-
575 cGy, n  7); VP, Cy, and TBI (1200-1575 cGy,
 5); VP, Cy, and BCNU (n  2); VP, Cy, and TBI
600 cGy, n  1); and ﬂudarabine (Flu) and TBI (200
Gy, n  1). GVHD prophylaxis in allogeneic cases
onsisted of CSA and MTX (n  81) and CSA and
ycophenolate mofetil (MMF) (n  1). At a median
ollow-up of 50 months, the 5-year OS and DFS were
oth 30%. Multivariate analysis demonstrated a sig-
iﬁcantly higher risk of relapse in patients in relapse at
ime of SCT (compared with remission at time of
CT, RR  3.9; P  .001), in mismatched related or
atched unrelated donor SCT (compared with autol-
gous/matched related donor SCT, RR  2.9; P 
005), and patients aged 33 years or older (compared
ith  33 years, RR  1.7; P  .042).
Iida et al. [61] described the outcomes of 46 pa-
ients with Ph ALL (50%  28 years old) treated in
R1 (n  18), CR2 (n  8), or with relapsed/
rimary refractory disease (n  20) with an allogeneic
CT at 7 Japanese centers from 1981 to 2000. Allo-
eneic donors were HLA–matched related (n  22),
LA–mismatched related (n  8), or unrelated (n 
6, HLA–match status not indicated). Conditioning
egimens consisted of Cy and TBI (1000-1500 cGy)
ther (n  23); Mel and TBI (1000-1500 cGy) 
ther (n  20); and Bu and Cy (n  3). GVHD
rophylaxis regimens consisted of CSA and MTX (n
33); tacrolimus and MTX (n  9); and other (n 
). The 5-year TRM was 26%. At a median follow-up
f 53 months, the 5-year DFS was signiﬁcantly higher
or those who underwent transplantation in CR1 ver-
us those who underwent transplantation with disease
38.5% versus 7.5%; P  .02).
Lee et al. [62] reported the results of 41 consecu-
ive adult (15 years) patients with precursor B-lin-
age ALL treated with an HLA–matched allogeneic
MT in CR1 (n  35) or CR2 (n  6) between 1994
Table 8. Comparison of Patient Characteristics and Outcomes from the Articles in the Related and Unrelated Donor Allogeneic Stem Cell Transplantation Section
Reference
Quality and
Strength of
Evidence
Patient
Populations No. of Patients
Median (range)
Age at Time of
Transplant
Treatment-
Related
Mortality
Median
Follow-Up
(mos) LFS/EFS/DFS
Significance
LFS/EFS/DFS OS
Significance
OS
Related vs. Unrelated Donor Allogeneic SCT
56 2 9 European centers Total 221
MRD 103
MUD 118
32 (17-62)
29 (17-57)
5 y
43%
50%
Not stated 5-y DFS
42%*
45%*
Not significant Not stated Not compared
Related and Unrelated Donor Allogeneic SCT
57 2 EBMT registry Total 508
Age >40 y 41
Age 16-40 y 467
43 (41-51)
24 (14-40)
Overall
37%
28%
19
32
Not stated Not compared Overall
36%
54%
P  .03
58 2 2 US centers Total 182†
CR1 41
CR>2 46
Rlps 95
29.4 (18-57.6) Day 100
34%
Not stated 5-y DFS
43%
23%
9%
P < .001 5 y
21%
Not compared
59 2 27 French centers
Ph ALL
Total 121‡
CR1 76
Other 45
35 (1-53) Overall
38%
29 Not stated Not compared 2 y
50%
17%
P < .0001
60 2 Single US center
Ph ALL
Total 90
Auto/MRD 39§
MisMRD/MUD 51
33 (2-56) Overall
30%
50 5-y DFS
30%
P  .005¶ 5 y
30%
Not compared
61 2 7 Japanese centers
Ph ALL
Total 46
CR>1 26
Rlps/Refr 20
28.5 (4-51) 5 y
26%
53 5-y DFS
38.5%
7.5%
P  .02 5 y
23%
Not compared
62 2 Single Korean
center
Total 41#
t(9;22) or t(4;11) 12
Other karyotype 29
27 (15-43) Overall
7%
36 3-y DFS
27.8%
68.8%
P  .001 Not stated Not compared
63 2 12 German centers
Ph ALL
Total 22 43.5 (17-57) Overall
36%
11.9 1-y DFS
25.5%
Not compared 1 y
44.8%
Not compared
64 2 4 International
trials
Total 27 50 (18-63) Day 100
19%
27 Not stated Not compared 2 y
31%
Not compared
65 2 13 German centers Total 22
NST as first 11
NST as second 11
38 (21-58) Overall
41%
16.5 Not stated Not compared Overall
27%
9%
Not significant
Auto indicates, autologous; CR1, ﬁrst complete remission; CR1, greater than ﬁrst complete remission; CR2, second or greater, complete remission; DFS, disease-free survival; EBMT, European Bone Marrow Transplant; EFS,
event-free survival; LFS, leukemia-free survival; MisMRD, mismatched related donor; MRD, matched related donor; MUD, matched unrelated donor; NST, nonmyeloablative stem cell transplant; OS, overall survival; Refr,
refractory; Rlps, relapse.
*Comparing patients transplanted in CR1.
†Includes 88 HLA-matched related, 26 HLA-mismatched related, 33 HLA-matched unrelated, and 35 HLA-mismatched unrelated donor BMTs.
‡75 Patients overlap with reference 8.
§Includes 8 autologous and 31 HLA-matched related donor SCTs.
Includes 37 HLA-matched unrelated donor and 14 HLA-mismatched related donor SCTs.
¶The multivariate analysis comparing the Auto/MRD vs. MisMRD/MUD groups yielded a relative risk of 2.9, P  .005, controlling for remission status and year of SCT. The 5-year DFS for this comparison was not stated.
#The article did not state the donor relation.
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2nd 1999 at a single Korean center. No information
as given regarding donor relation. Conditioning reg-
men consisted of Cy and TBI (1320 cGy fraction-
ted); GVHD prophylaxis was CSA and MTX. Pa-
ients were classiﬁed as having an unfavorable
aryotype if they had Ph ALL (n  10) or t(4;11) (n
2); all others, including patients with normal cyto-
enetics, were classiﬁed as having a favorable karyo-
ype (n  29). At a median follow-up of 36 months,
he TRM was 7.3%. The 3-year DFS was signiﬁcantly
etter for those with a favorable karyotype (68.8%
ersus 27.8%; P  .001). Multivariate analysis yielded
nfavorable karyotype (RR  11.6; 95% conﬁdence
nterval 2.9-46.3; P  .001) and BMT in CR2 (RR 
.9; 95% conﬁdence interval 1.5-31.1; P  .013) as
igniﬁcant independent predictors of a lower DFS.
Wassman et al. [63] evaluated 22 adult (17 years)
atients with Ph ALL treated with an allogeneic
CT after salvage therapy with imatinib mesylate.
atients underwent transplantation at 12 German
enters from 2000 to 2001. Allogeneic donors were
LA–matched related (n  9), HLA–mismatched re-
ated (n  1), HLA–matched unrelated (n  9), or
LA–mismatched unrelated (n  3). Patients re-
eived imatinib mesylate as part of a phase II trial
re-SCT as a single daily oral dose of 600 mg, which
as continued until severe toxicity or disease progres-
ion occurred; imatinib therapy was discontinued in all
atients 1 to 14 days before starting the SCT condi-
ioning regimen. Sixteen patients achieved a complete
ematologic or molecular response within 4 weeks of
nitiation of imatinib therapy. Conditioning regimens
onsisted of Cy and TBI  VP (dose of TBI not
ndicated, n 11); Cy, TBI, and radioimmunotherapy
n  2); Bu and Cy (n  2); or other (n  9). GVHD
rophylaxis regimens were CSA, MTX, and ATG (n
5); CSA and ATG (n  3); CSA, ATG, and MMF
n  2); CSA and MMF (n  2); CSA and MTX (n 
); or other combinations (n  8). At a median fol-
ow-up of 11.9 months post-SCT, the 1-year DFS and
S for all patients were 25.5% and 44.8%, respec-
ively.
Martino et al. [64] retrospectively reported the
igure 5. Kaplan-Meier estimation of disease-free survival in pa-
ients receiving transplantation from a matched related or unrelated
onor in ﬁrst complete remission. Reprinted with permission [56].esults of 27 adult (18 years) patients with ALL p
0reated in CR1 (n  4), CR2 (n  10), Rel1 (n 
1), or with primary refractory disease (n  2) with a
educed intensity conditioning regimen allogeneic
CT on one of 4 multicenter prospective studies ac-
rued through 2001. Patients received a reduced in-
ensity regimen as a result of age older than 55 years,
rior autologous BMT, or severe comorbidity (pul-
onary, cardiac, or other organ dysfunction contra-
ndicating myeloablative conditioning). Allogeneic
onors were HLA–matched related (n  15),
LA–mismatched related (n 4), HLA–matched un-
elated (n  4), and HLA–mismatched unrelated (n 
). Reduced intensity conditioning regimens consisted
f Flu (90-150 mg/m2) and Mel (140 mg/m2) (n 21);
lu, Mel, and Ara-c (n  3); Flu (90-150 mg/m2),
hiotepa (10 mg/kg), and Cy (n  2); and Flu and TBI
single fraction 200 cGy, n  1). GVHD prophylaxis
onsisted of CSA and MTX (n  13); tacrolimus and
TX (n  11); CSA and Campath (n  2); and CSA
nd MMF (n  1). Day 100 TRM was 18.5%; the
ncidence of grades II to IV acute GVHD was 48%. At
median follow-up of 26.7 months, the 2-year OS was
1% and the 2-year probability of disease progression
as 49%.
Arnold et al. [65] described a prospective pilot
tudy of nonmyeloablative conditioning for allogeneic
CT in 22 adult (21 years) patients with high-risk
LL conducted at 13 German centers (time period
as not stated in the article). Allogeneic donors were
LA–matched related (n  13), HLA–mismatched
elated (n  1), or HLA–matched unrelated (n  8).
igh-risk was deﬁned by GM-ALL criteria: active
isease (n  16), Ph ALL in CR1 (n  1), high
BC at diagnosis and in CR1 (n  1), Ph ALL in
R2 (n  1), T-lineage ALL in CR2 (n  1), CR2
ith relapse after prior SCT (n  1), and graft failure
fter prior SCT (n 1). A total of 11 patients received
onmyeloablative SCT as their ﬁrst SCT; 11 patients
eceived it as salvage after a failed prior autologous or
llogeneic SCT. Sites of prior relapse and duration of
R1 were not stated. Conditioning regimen consisted
f Flu and Bu  ATG. GVHD prophylaxis consisted
f CSA alone (n  10); CSA and MMF (n  7); CSA
nd MTX (n  3); MTX alone (n  1); and CSA and
rednisolone (n  1). At a median follow-up of 16.5
onths, 9 patients (41%) died of GVHD or infection,
patients (36%) died of leukemia, and one died of
raft failure. Donor lymphocyte infusions were given
o 7 patients for residual/refractory disease post-SCT.
our patients were alive and in CR 5 to 30 months
ost-SCT.
UTOLOGOUS VERSUS ALLOGENEIC BMT IN
DULT ALL
Table 9 summarizes the grading criteria, study
opulations, patient characteristics, and outcomes
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Cytotoxic Therapy with SCT for Adult ALL
Brom adult studies included in the Autologous versus
llogeneic BMT section. Evidence in this section is
aken from self-described studies of adult populations,
ll of which included patients at least 13 years of age.
vidence is presented with the highest quality studies
rst; studies of equal quality are presented in descend-
ng order with the largest sample size ﬁrst.
Hunault et al. [66] performed a prospective mul-
icenter (21 institutions) phase III trial between 1994
nd 1998 for adult (15 and 59 years) patients with
LL in CR1 with a biologic randomization between
atients younger than 50 years with an HLA–identical
ibling donor (n  41) who received a related alloge-
eic SCT (n  39) and patients older than 50 years (n
9) or without an HLA–identical sibling donor (n 
06) who received an autologous PBSCT (n  19) or
MT (n  72). Patients were eligible for the trial if
hey had one or more of the following risk factors: age
lder than 35 years; B-lineage ALL; WBC greater
han 30  109/L; cytogenetic abnormalities including
(4:11), t(9;22), t(1;19), or BCR-ABL; or failure to
chieve CR1 after one induction course. Both alloge-
eic and autologous SCT patients received VP, Cy,
nd TBI (1200 cGy in 6 fractions) as the conditioning
egimen. GVHD prophylaxis regimens were not in-
icated. At a median follow-up of 5.1 years, the related
onor group had a signiﬁcantly improved 6-year DFS
72% versus 33%; P  .0004) and 6-year OS (75%
ersus 39%; P  .0027; Figure 6) compared with the
o donor group. This comparison was restricted to
he 106 patients younger than 50 years who were
ligible for an allogeneic SCT and was performed on
n intent-to-treat basis.
Attal et al. [67] performed a prospective phase III
rial at 9 French centers between 1990 and 1992 with
biologic randomization: adult (15 years) patients
ith ALL in CR1 with (n  43) or without (n  77)
n HLA–identical sibling donor received a T-cell re-
lete allogeneic (n 41) or unpurged autologous (n
4) BMT, respectively. BMT was performed in 83%
f the no donor and 95% of the patients in the donor
roup; however, all analyses were performed on an
ntent-to-treat basis. In all, 12% of the donor group
nd 18% of the no donor group had Ph ALL.
atients with autologous BMT were further random-
zed to receive (n  30) or not receive (n  30) IL-2
or 5 cycles every other week after transplantation
nce the following post-BMT criteria were fulﬁlled:
1) CR; (2) WBC recovery; and (3) adequate kidney,
iver, cardiac, and pulmonary function. The condi-
ioning regimen for both autologous and allogeneic
ases was Cy and TBI (1200 cGy, fractionated).
VHD prophylaxis for patients with allogeneic BMT
as CSA and MTX. The 3-year DFS in the HLA–
dentical sibling group versus the no HLA–identical
ibling group was 68% versus 26%; P  .001 (Figure
). The corresponding TRM rates were 12% and 2%. r
B&MTn the autologous BMT group, there was no signiﬁ-
ant difference in the 3-year DFS (29% versus 27%; P
not signiﬁcant) or 3-year OS (28% versus 36%; P
ot signiﬁcant) in the patients who did or did not
eceive posttransplantation IL-2.
Dombret et al. [8] conducted a prospective phase
II trial at 33 French and Belgian centers between
994 and 2000 (LALA-94 trial) in patients (15 years
ld) with newly diagnosed untreated Ph or BCR-
BL with B-lineage ALL. A total of 154 patients
ere randomized to receive one of two induction
herapy regimens, followed by a single consolidation/
alvage regimen of intermediate-dose Ara-c and mi-
oxantrone. A total of 103 patients in CR after inter-
ediate-dose Ara-c and mitoxantrone were eligible
or a biologic randomization based on donor availabil-
ty to either a matched related BMT (n  46),
atched unrelated BMT (n  14), or autologous
BSCT (n 43) at 3 months after consolidation. The
onditioning regimen for autologous and related allo-
eneic BMT was Cy, VP, and TBI (1000cGy in 1
raction or 1200 cGy in 6 fractions) but varied by
enter for unrelated donor BMT. GVHD prophylaxis
egimens varied by center. Transplantation was actu-
lly performed in 44 (96%) of the matched related, 12
86%) of the matched unrelated, and 24 (56%) of the
utologous BMT groups; however, the results are
ased on an intent-to-treat approach. There was no
ifference in OS in the matched related versus unre-
ated BMT groups; therefore, the data were analyzed
s donor (n  60) versus no donor (n  43) groups.
he 3-year OS of the no donor group was signiﬁ-
antly lower than the donor group (12% versus 37%;
 .02; Figure 8), even after adjustment for age,
eukocyte count, and number of chemotherapy
ourses to achieve CR1. The 3-year relapse incidence
as signiﬁcantly higher in the no donor versus donor
roup (90% versus 50%; P  .001). The 2-year prob-
bility of death in CR was equivalent in the donor
ersus no donor groups (24% versus 24%; P  not
igniﬁcant).
Ringden et al. [68] compared 1416 autologous,
46 HLA–matched sibling allogeneic (who did not
evelop GVHD), and 23 identical twin BMT patients
reated for ALL in CR1 between 1987 and 1999 and
eported to the EBMT to determine if there was a
raft-versus-leukemia effect in the absence of GVHD.
f patients, 17% were younger than 17 years at time
f BMT; however, this is an aggregate of patients with
ML and ALL. Autologous BMT recipients received
urged (n  759), unpurged (n  1792), or unknown
urged/unpurged (n  2649) grafts. The majority of
llogeneic BMT recipients received CSA and MTX
70%) for GVHD prophylaxis; another 14% received
-cell depleted grafts. Of all patients, 48% received
BI-containing conditioning regimens, another 16%eceived Bu and Cy, and 36% received other combi-
21
Table 9. Comparison of Patient Characteristics and Outcomes from the Articles in the Autologous Versus Allogeneic Stem Cell Transplantation Section
Reference
Quality and
Strength of
Evidence
Patient
Populations No. of Patients
Median (range)
Age at Time of
Transplant
Treatment-
Related
Mortality
Median
Follow-Up
(mos) LFS/EFS/DFS
Significance
LFS/EFS/DFS OS
Significance
OS
66 1 GOELAL02 trial Total 156
Rel donor 41
No Rel donor 115
33 (15-59) 6 mo
15%
3%
61 6-y DFS
72%
33%
P  .0004* 6 y
75%
39%
P  .0027*
67 1 Multicenter French
trial
Total 120
Rel donor 43
No Rel donor 77
31 (15-55) Overall
12%
2%
27
25
3-y DFS
71%
30%
P < .001 Not stated Not compared
8 1 LALA-94 trial
Ph ALL
Total 103
Allo donor 60†
No donor 43
Not stated 2 y
24%
24%
54‡ Not stated Not compared 3 y
37%
12%
P  .02
68 2 EBMT registry§ Total 1785
Auto 1416
Sib Allo 346
Identical twin 23
34 (1-77)¶
27 (1-66)¶
30 (1-70)¶
2 y
9%
9%
17%
32 2 y
44%
61%
54%
P < .0001# Not stated Not compared
69 2 Single US center Total 36
Auto BMT 23
Allo BMT 13
Not stated Overall
12%
8%
Not stated Overall DFS
21%
43%
P  .0001 Median OS
(mos)
48
12
P  .0001
70 2 Single Italian
center
Total 79
Auto 39
Allo 40
21 (10-53)
25 (8-54)
Overall
5%
30%
158
99
10-y EFS
37.1%
46.9%
Not stated Not stated Not compared
71 2 Single French
center
Total 63
Auto BMT 34
Allo BMT 29
29 (16-59)
24 (16-41)
6 mo
3%
24%
54
83
27%
62%
P < .06
26%
61%
Not significant
72 2 Single French
center
Total 47
Auto 22
Rel Allo 25
47 (31)
36 (22)
Overall
9%
20%
25
42
Overall DFS
40%
71%
Not stated Overall
62%
71%
Not stated
73 2 Single US center Total 36
Auto BMT 22
Allo BMT 14
28 (18-54)
31 (19-50)
Overall
18%
Not stated
78
Not stated
Overall DFS
20%
Not stated
Not significant Not stated Not significant
74 2 Multicenter French
trial
Total 34
Auto BMT 18
Allo BMT 16
32 (16-49)
29 (18-46)
Overall
0%
38%
Overall
Not stated 4-y EFS
17%
33%
Not compared Not stated Not compared
75,76 2 4 German Centers
Ph ALL
Total 24
Auto 5
Rel Allo 13
Unrel Allo 6
28.5 (2-60)
24 (6-48)
30 (4-60)
16 (2-45)
25%
0%
38%
17%
45 3-y DFS
Not stated
46%#
Not stated
Not compared 3-y
Not stated
50%**
Not stated
Not compared
77,78 2 Single Spanish
center
Total 23
Auto 9
Allo 14
30 (16-62) Overall
11%
29%
44 Not stated Not compared Not stated Not compared
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F
igure
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D
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w
as
signiﬁcantly
superior
(P
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.001)
for
patients
w
ith
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H
L
A
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(dashed
line)than
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w
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outan
H
L
A
-identicalsibling
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line).R
eprinted
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Table 9. Continued
Reference
Quality and
Strength of
Evidence
Patient
Populations No. of Patients S
Significance
LFS/EFS/DFS OS
Significance
OS
79 2 Single UK center
Ph ALL
Total 20††
Auto BMT 9
Allo BMT 11
Not stated Not stated Not compared
ALL indicates acute lymphoblastic leukemia; Allo, allogencic; Auto, autolo vival; EBMT, European Group for Blood and Marrow
Transplant; EFS, event-free survival; LALA, Leucémie Aiguë Lymphob leukemia-free survival; OS, overall survival; Rel, related;
Sibl, sibling; Unrel, unrelated; UK, United Kingdom.
*The comparison of related donor vs. no donor groups was restricted to th c SCT if a donor was available.
†Includes 46 with matched related and 14 with matched unrelated donors; underwent transplantation.
‡Median follow-up from time of initial randomization before induction the
§There is some overlap between this study and references 30, 32, and 33.
Includes only HLA-matched sibling allo BMT patients who did not develo
¶Median age includes AML and ALL patients. ALL patients are 39% of th
#Comparing auto vs. sibling allo groups.
**DFS and OS is given for the 15 relatedunrelated allogeneic BMT patie
††A total of 5 patients overlap with reference 18.
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A
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m
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follow
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of
32
m
onths,
the
2-year
probability
of
relapse
w
as
51%
in
the
autolo-
gous,33%
in
the
siblingsw
ithoutG
V
H
D
,and
35%
in
the
identicaltw
in
transplantation
groups
(P

.0001).
T
he
2-year
L
FS
w
as
44%
,
61%
,
and
54%
,
respec-
tively,in
these
groups
(P

.0001).
Sotom
ayor
et
al.
[69]
perform
ed
a
trial
of
a
se-
quentialtherapy
regim
en
in
85
consecutive
unselected
adult
(
17
years)
patients
w
ith
A
L
L
at
a
single
U
S
center
betw
een
1983
and
1993.
T
he
sequential
regi-
m
en
consisted
of
one
of
tw
o
induction
therapies,fol-
low
ed
by
intensiﬁcation
w
ith
A
ra-c
and
daunorubicin.
P
atients
in
C
R
1
w
ith
an
H
L
A
–identicalsibling
donor
received
an
allogeneic
B
M
T
(n

13);those
in
C
R
1
w
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no
suitable
donor
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autologous
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M
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
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m
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late
intensiﬁcation
(n

17)
for
those
patients
ineligible
for
autologous
or
alloge-
Median (range)
Age at Time of
Transplant
Treatment-
Related
Mortality
Median
Follow-Up
(mos) LFS/EFS/DF
35 (9-55)
27 (3-37)
2 y
11%
27%
17
26
3-y DFS
25.6%
21.8%
gous; BMT, bone marrow transplantation; DFS, disease-free sur
lastique de l’Adulte (Adult Acute Lymphoblastic Leukemia); LFS,
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2lder age. Conditioning regimens were varied, but
onsisted mainly of Cy and TBI (n  24) or Bu, Cy,
nd VP (n  12); GVHD prophylaxis consisted of
SA or T-cell depletion. Median follow-up time of
he surviving patients was not stated. The 4-year DFS
as signiﬁcantly better in the allogeneic BMT group
ompared with the autologous BMT group (43% ver-
us 21%; P .0001). Median OS was also signiﬁcantly
onger in the allogeneic BMT group (48 versus 12
onths; P  .0001).
Annaloro et al. [70] presented the results of 79
atients with ALL (50%  21 years old) who received
n autologous (n 39) or allogeneic (n 40) BMT at
single Italian center from 1984 to 2002. Allogeneic
onors were HLA–matched related (n  36), HLA–
atched unrelated (n  3), or HLA–mismatched re-
ated (n  1). In all, 17 autologous and 19 allogeneic
MT recipients were in CR1 at time of transplanta-
ion; the remaining patients had more advanced dis-
ase. Conditioning regimens consisted of Cy, Ara-c,
nd TBI (1000 cGy in 3 fractions, n  76 autologous
nd related allogeneic BMT), and Cy and TBI (1320
Gy in 11 fractions, n  3). GVHD prophylaxis con-
isted of CSA and MTX (n  39), and CSA and MP
n  1). Median duration of CR1 in the autologous
MT group was 13 months and in the allogeneic
roup was 14 months. At a median follow-up of 158
onths in the autologous and 99 months in the allo-
eneic BMT groups, the 10-year EFS were 37.1% and
6.9%, respectively (P not stated).
Vey et al. [71] retrospectively analyzed 63 adult
15 years) patients with ALL treated in CR1 with
ither autologous (n  34, lacking an HLA–identical
ibling donor) or allogeneic (n  29, with an HLA–
dentical sibling donor) BMT between 1981 and 1991
igure 8. Kaplan-Meier landmark survival estimates (with a 90-day
andmark period) for patients eligible for SCT according to the
xistence of an allogeneic donor (N  103 patients) (relative risk in
he no-donor group, 1.71; 95% conﬁdenced interval, 1.09 to 2.68;
 .02 by the log-rank test). Reprinted with permission [8].t a single French center. All patients had at least one (
4oor prognostic feature: age older than 30 years;
BC at diagnosis greater than 25  109/L; CNS
nvolvement; B-lineage; t(4;11) or t(9;22); or time
rom diagnosis to CR1 longer than 4 weeks. Condi-
ioning regimens included Cy and TBI; Mel and TBI;
r Cy, Mel, and TBI. GVHD prophlyaxis in the
llogeneic BMT group included MTX (n  5), CSA
n  9), or CSA and MTX (n  15). In addition, 7
atients with allogeneic BMT received T-cell de-
leted grafts. Autologous BM was purged in vitro in 24
atients with anti-CD10, anti-DR, anti-CD5ricin A
hain, 4-hydroperoxycyclophosphamide, ASTA-Z, or
P. At a median follow-up of 5.5 years, the 6-year
FS was higher for the allogeneic compared with the
utologous BMT group (62% versus 27%; P  .06).
Blaise et al. [72] performed a pilot trial of purged
utologous (n  22) and matched related allogeneic
n 25) BMT in patients with high-risk ALL (78% of
he autologous and 88% of the allogeneic group were
15 years old) in CR1 from 1981 to 1987 in a single
rench center. Patients without a matched sibling
eceived an autologous BMT. Patients at high risk
ere deﬁned as older than 15 years at diagnosis, 15
ears or younger with a WBC greater than 100 
09/L at diagnosis, or failure to achieve a CR within 1
onth of induction therapy. All patients received TBI
ith Mel, Cy, or Mel and Cy as the conditioning
egimen; GVHD prophylaxis was MTX or CSA or
oth (n 17) or T-cell depletion (n 8). At a median
ollow-up of 31 and 22 months in the autologous and
llogeneic groups, there were no statistically signiﬁ-
ant differences in DFS or OS.
Soiffer et al. [73] treated 22 adult (18 years)
atients with B-lineage ALL with an autologous BMT
urged in vitro with J5 and J2 monoclonal antibodies
CD10/CD9) plus rabbit complement. All patients
eceived Cy and TBI (1200-1400 cGy, fractionated) as
onditioning; the ﬁrst 9 patients also received Ara-c.
o patients with autologous BMT had HLA–identical
ibling donors. All patients underwent transplantation
n CR2 (n  21) or had primary induction failures
nd achieved CR1 with subsequent chemotherapy (n
1). These patients with autologous BMT were com-
ared with a concurrent cohort of 14 adult patients
ith ALL treated in CR2 or CR3 with T-cell depleted
anti-CD6 monoclonal antibody plus complement)
LA–identical related allogeneic BMT. Patients with
llogeneic BMT were treated with the same condi-
ioning regimen as the autologous group and met
imilar eligibility criteria. There was no signiﬁcant
ifference between the autologous and allogeneic
MT groups with respect to DFS or OS (survival and
not stated in original article). In the autologous
MT group, only age was a prognostic factor, where
atients younger than 28 years at time of BMT had a
onger DFS than those who were older than 28 years
45% versus 0%; P not stated).
i
i
ﬁ
w
t
a
H
a
c
f
p
v
c
n
3
g
o
o
y
(
d
c
1
o
1
A
p
t
O
c
t
p
1
1
w
a
t
o
m
g
g
t
t
g
(
1
t
p
C
l
o
B
c
T
t
t
s
F
A
f
c
a
T
N
C
n
s
v
i
a
r
A
t
v
t
d
w
a
s
p
d
o
a
i
A
s
f
s
d
(
a
y
i
f
e
d
o
D
s
Cytotoxic Therapy with SCT for Adult ALL
BIfrah et al. [74] performed a prospective random-
zed trial of granulocyte macrophage colony–stimulat-
ng factor versus placebo after induction and intensi-
cation chemotherapy in 67 adult (15 years) patients
ith ALL between 1990 and 1992 at 16 French cen-
ers. After induction therapy, all patients who achieved
CR1, were younger than 45 years old and had an
LA–identical sibling donor (n  18), underwent
llogeneic BMT (n  16); all others received one
ourse of an intensiﬁcation chemotherapy regimen
ollowed by unpurged autologous BMT (n  18). For
atients with allogeneic BMT, conditioning regimens
aried by center. For patients with autologous BMT,
onditioning regimens were Cy and TBI (1200 cGy,
 16) or Bu and Cy (n  2). The 4-year EFS was
3% for the allogeneic and 17% for the autologous
roups (statistical signiﬁcance tests comparing autol-
gous versus allogeneic BMT were not performed).
Kroger et al. [75,76] retrospectively assessed the
utcomes of 24 patients with Ph ALL (79%  18
ears old at time of BMT) treated with an autologous
n  5) or allogeneic (n  13 related, 6 unrelated
onor) BMT between 1990 and 1997 at 4 German
enters. Remission status at BMT was 19 CR1, 2 CR2,
PIF, and 2 relapse. Conditioning regimens consisted
f VP, Cy, and TBI (n  23) or VP, Cy, and Bu (n 
); GVHD prophylaxis consisted of CSA and MTX 
TG. At a median follow-up of 45 months in all
atients, the DFS was 37.5%. Allogeneic BMT pa-
ients treated in CR1 (n  15) had a 3-year DFS and
S of 46% and 50%, respectively.
Martino et al. [77,78] described the results of 22
onsecutive adult (16 years) patients with ALL
reated with an autologous (n  9, 8 of which were
urged) or an HLA–matched related allogeneic (n 
4) BMT at a single Spanish center from 1988 to
997. Conditioning and GVHD prophylaxis regimens
ere not stated. All patients with autologous BMT
nd 9 patients with allogeneic BMT were in CR2 at
ime of BMT; 5 with allogeneic BMT were in second
r greater relapse. At a median follow-up of 44
onths, the median OS was 15.4 months for autolo-
ous and was not yet reached for patients with allo-
eneic BMT (P  .2).
Dunlop et al. [79] reported 19 patients (one pa-
ient was 18 years old) with Ph ALL who were
reated with 20 transplantation procedures (9 autolo-
ous or 11 matched related allogeneic BMT) in CR1
n  12), CR2 (n  3), or relapse (n  5) between
986 and 1995 at one United Kingdom center. Pa-
ients with autologous BMT received Mel  TBI and
atients with allogeneic BMT received TBI and Mel,
y, or VP as conditioning regimen. GVHD prophy-
axis was CSA  MTX. No patients received purged
r T-cell depleted grafts. Patients with autologous
MT received maintenance therapy with daily 6-mer-
aptopurine and weekly MTX for 2 years post-BMT. d
B&MThere was no signiﬁcant difference in DFS between
he autologous and allogeneic BMT groups. OS for
he whole cohort was 37.5% at 3 years and was not
peciﬁed for the two BMT groups.
UTURE DIRECTIONS
dditional Ongoing Studies
Several studies have been published in abstract
orm, were recently completed, or are currently ac-
ruing patients but address critical issues that may
ffect the treatment recommendations made above.
he Eastern Cooperative Oncology Group (ECOG),
ational Cancer Institute, and Medical Research
ouncil have sponsored a randomized phase III inter-
ational multicenter trial (UKALL XII/ECOG2993
tudy) of consolidation/maintenance chemotherapy
ersus SCT in adult (15-65 years) patients with ALL
n CR1 [80-82]. Patients younger than 50 years are
ssigned to receive a related allogeneic SCT (an un-
elated donor SCT is allowed for patients with Ph
LL) if a suitable donor is available, otherwise pa-
ients are randomized to receive an autologous SCT
ersus consolidation/maintenance chemotherapy. Pa-
ients age 50 to 65 years are randomized to consoli-
ation chemotherapy versus autologous SCT. Patients
ith Ph ALL receive maintenance imatinib mesylate
fter autologous or allogeneic SCT.
The Cancer and Leukemia Group B has spon-
ored a phase II multicenter trial in adult (15-59 years)
atients with Ph ALL. Patients receive a related
onor allogeneic SCT if a suitable donor is available,
therwise receive an autologous SCT or chemother-
py if transplantation is not an option. Patients receive
matinib mesylate both before and after SCT.
reas of Needed Research
After reviewing the evidence and highlighting the
tudies that are in progress, the panel recommends the
ollowing as the most important areas of needed re-
earch: monitoring of minimal residual disease and
isease control before SCT; comparison of nonfamily
unrelated bone marrow or cord blood) donor versus
utologous SCT; deﬁnition of high-risk groups, be-
ond Ph status, in CR1; evaluation of the impact of
matinib and other tyrosine kinase inhibitors on SCT
or Ph ALL; analysis of the graft-versus-leukemia
ffect in reduced intensity versus myeloablative con-
itioning regimens; and outcomes data for SCT in
lder (50 years) patients with ALL.
ISCUSSION
The authors strongly recommend methodology
tandardization, including study design, end point
eﬁnitions, and reporting of study results. Multi-
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2enter randomized phase III comparative trials with
arge enrollments and high statistical power are
equired to advance the ﬁeld more constructively
han single institution phase II trials with one treat-
ent arm or retrospective multicenter or registry
tudies. In addition, publication of preliminary analy-
es should be reserved for studies in which the trial
as terminated early because of excessive toxicity or
igniﬁcantly inferior or superior results. For most
tudies, 3 years of follow-up in surviving patients is
eeded to detect signiﬁcant differences between treat-
ent arms. The authors advocate prompt reporting of
ature data in full-length article format. Abstracts do
ot adequately convey the full details of the study
esign or patient characteristics to meet evidence-
ased criteria for inclusion in systematic reviews, nor
or making a true assessment of the widespread appli-
ability or impact of the treatment outside the scope of
he trial.
Much of today’s therapies for cancer result from
he clinical trial process. It is currently estimated
hat less than 5% of adults eligible to participate in
ancer clinical trials actually enroll in a trial. The
uthors acknowledge the importance of removing
arriers to participation in clinical trials, which may
nclude patients’ reluctance to be randomized, lack
f patient access to clinical trials (e.g., geographic,
ransportation, cultural), ﬁnancial constraints (no or
ncomplete insurance coverage for trial expenses),
tringent trial eligibility criteria, and reluctance of
ommunity physicians to refer patients for clinical
rial participation.
An additional challenge to the low rate of partic-
pation in clinical trials by adult patients with cancer is
he relatively low incidence of adult ALL. According
o the Surveillance, Epidemiology, and End Results
ancer Statistics Review [83], it is estimated that there
ill be approximately 1700 to 1800 new cases of adult
20 years) ALL diagnosed in the United States in
005. Thus, there is a small number of adult ALL
ases that may be eligible for enrollment in a clinical
rial examining any one of numerous therapeutic op-
ions.
IMITATIONS OF THIS EVIDENCE-BASED
ITERATURE REVIEW
There are limitations to any evidence-based re-
iew of the published literature. The criteria for this
eview included reliance on published data, specif-
cally peer-reviewed articles published since 1980.
npublished data, which were not included in this
eview, often represent negative ﬁndings and do not
ndergo peer review. We also excluded data pub-
ished in abstract form because the data are usually v
6ot peer reviewed, are presented in an abbreviated
ormat, and usually represent preliminary, not ﬁnal
ata analyses. In addition, published literature may
ot address the management of all disease-speciﬁc
linical situations.
Limitations speciﬁc to this review topic include
he variability in reporting patient characteristics pre-
CT, changing treatment modalities over time, and
he paucity of randomized controlled trial data. The
uccess of SCT is affected by prior sites of relapse,
resence of extramedullary disease, and duration of
R1; many studies did not report this information in
he published article making it difﬁcult to compare
CT outcomes across studies. Chemotherapy regi-
ens, particularly those used for salvage, and pre-
CT conditioning regimens and post-SCT supportive
are have changed during the more than 20 years of
rials included in this review. The effectiveness of
alvage regimens impacts attainment of CR2, which
n turn impacts the effectiveness of SCT. Finally,
andomized controlled trial data were lacking in many
reas of this review leading to several treatment rec-
mmendations based on small prospective studies
nd/or large retrospective registry reports. For exam-
le, the expert panel could not make recommenda-
ions for or against the use of SCT for patients not in
R because available evidence was insufﬁcient.
UTURE INITIATIVES
This comprehensive systematic review of the
vailable evidence for the role of cytotoxic therapy
ith SCT in the therapy of adult ALL is the fourth in
series of sequential articles sponsored by the
SBMT. Each review will summarize the evidence
egarding the role of cytotoxic therapy with SCT in
he treatment of a speciﬁc disease using deﬁned meth-
dology and grading criteria. The next review in the
eries will address the role of SCT in the therapy of
ediatric acute myeloid leukemia.
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Cytotoxic Therapy with SCT for Adult ALL
Bppendix A. Glossary of Terms
ALC Absolute lymphocyte count
ALL Acute lymphoblastic leukemia
ASBMT The American Society for Blood and Marrow Transplantation
Ara-c Cytarabine; cytosine arabinoside
ATG Anti-thymocyte globulin
AUL Acute unclassified leukemia
BMT Bone marrow transplantation
Bu Busulfan
CNS Central nervous system
CR Complete remission
CR1 First complete remission
CR>1 Greater than first complete remission
CR>1 First or greater complete remission
CR2 Second complete remission
CR>2 Second or greater complete remission
CR3 Third complete remission
CR>3 Third or greater complete remission
CSA Cyclosporine
Cy Cyclophosphamide
DFS Disease-free survival
EBMT European Group of Blood and Marrow Transplant
EFS Event-free survival
Flu Fludarabine
GVHD Graft versus host disease
HLA Human leukocyte antigen
IBMTR The International Bone Marrow Transplant Registry
JALSG Japan Adult Leukemia Study Group
LALA Leuc´emie Aiguë Lymphoblastique de l’Adulte
LFS Leukemia-free survival
Mel Melphalan
MMF Mycophenolate mofetil
MP Methylprednisolone
MTX Methotrexate
NMDP National Marrow Donor Program
OS Overall survival
PBSCT Peripheral blood stem cell transplantation
Ph Philadelphia chromosome positive
RCTs Randomized controlled trials
RFS Relapse-free survival
RR Relative risk
SCT Hematopoietic stem cell transplantation
TBI Total body irradiation
TRM Treatment-related mortality
UKALL United Kingdom Acute Lymphoblastic Leukemia
VP Etoposide
WBC White blood cell count
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